WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.084
Volume 12, Issue 22, 583-650. Review Article ISSN 2277–7105

NEURODEGENERATIVE DISEASE: ALZHEIMER'S DISEASE

Vishal Thakur*[1], Mansi Sharma[2], Vishal Sharma[3], Dr. Akriti Singh[4], Suhaib Farooq[5]

[1,2]Research Scholar, School of Pharmacy and Emerging Science, Baddi Umversity of Emerging Sciences and Technology, Baddi, Himachal Pradesh.

[3,4]Assistant Professor, School of Pharmacy and Emerging Science, Baddi University of Emerging Sciences and Technology, Baddi, Himachal Pradesh.

[5]Lovely professional university Punjab.

Article Received on
28 October 2023,

Revised on 17 Nov. 2023,
Accepted on 07 Dec. 2023

DOI: 10.20959/wjpr202322-30616

***Corresponding Author**
Vishal Thakur
Research Scholar, School of Pharmacy and Emerging Science, Baddi Umversity of Emerging Sciences and Technology, Baddi, Himachal Pradesh.

ABSTRACT

Alzheimer's disorder(AD) is a neurological infection that impacts the old. Promotion annihilates synapses and causes cognitive decline and issues in thinking and conduct. The neuropathological sign of AD incorporates an amyloid plaque, neurofibrillary tangles, neuronal misfortune, and synaptic misfortune also.Progressive brain deterioration, as well as reduced activities of daily living and behavioral disorders,portray this condition. Dementia is the clinical state of Alzheimer's sickness (AD), which often begins with an unobtrusive and ineffectively saw the cognitive decline and continuously deteriorates with the result of deadening. Alzheimer's sickness is the main source of dementia. Dementia is caused due to a variety of neurodegenerative and cerebrovascular diseases, especiallyamong the elderly, proteotoxic stress, together with abnormalities in the ubiquitin-proteasome and autophagosomal/lysosomal systems. This disease (AD) is a synaptic dysfunction condition characterized by failures of molecular, cellular, and macro-scale cortical circuitry systems, with a preference for a cognitively eloquent brain. Changes in the APP, PSEN1, and PSEN2 qualities are connected with this condition. Diet and nourishment likewise play a huge impact in the turn of events and avoidance of Alzheimer's illness. The biomarker used to recognize dementia ought to have the option to recognize various reasons for dementia and identify it earlyon induced pluripotent stem cells have also been shown to

be a successful treatment for curing this condition. The goal of this review is to shed insight on the path that leads to this disease and how stem cells can be used to treat it.

KEYWORDS: Alzheimer's disease; Amyloid precursor protein**;** Neurofibrillary tangles; Oxidative stress; Genetics.

1. INTRODUCTION

The lack of neurons and growing breakdown are indications of neurodegenerative issues. The deposition of proteins with changed physicochemical characteristics, commonly known as misfolded proteins, is an essential aspect. The expression "conformational messes" alludes to when a physiologic protein's primary conformity changes, prompting an adjustment of capacity or possibly unsafe intra-or extracellular collection (Robin and David, 1997). Proteotoxic stress and its chaperon anomalies in the ubiquitin-proteasome and autophagosomal/lysosomal frameworks, oxidative pressure, customized cell demise, furthermore, neuroinflammation are ordinary components of neurodegenerative contaminations. Additionally, protein inconsistencies that depict neurodegenerative issues can exist before the start of clinical incidental effects (Gibb et al., 1988; Dugger et al., 2014). An individual can have more than one neurodegenerative disease process (Duggeret al., 2014; Uchikado et al., 2006).

Alzheimer's illness (AD), is a normal kind of dementia that is portrayed as a slowly safe neurodegenerative contamination depicted by neuritis plaques and neurofibrillary tangles because of amyloid-beta peptide (Aβ) aggregation in the most impacted region of the mind, the medial temporal lobe and neocortical structures(Harris and Robin, 2012) discovered amyloid plaques and a huge loss of neurons, describing the illness as a catastrophic cerebral cortex disease. In his 8th edition psychiatric handbook, Emil Kraepelin identified this medical ailment of Alzheimer's disease for the first time (Gabriele et al., 2011; Serrano et al., 2011). Inebriations, contaminations, anomalies in the aspiratory and circulatory frameworks, which produce a decrease in the oxygen supply to the mind, nourishing lacks, vitamin B12 deficiency, tumors, and other conditions can all cause progressive loss of cognitive skills(Terry and Davies, 1980; Rathmann and Conner,1984).

2. Epidemiology

The study of disease transmission of Alzheimer's sickness and different reasons for dementia are joined(Peter Nelson et al., 2011; Boyle et al., 2017). Dementia is caused due to a variety

of neurodegenerative and cerebrovascular diseases, especiallyamong the elderly(Kapasi et al., 2017; Karanth et al., 2020). To be sure, one review took a gander at 184 individuals who fit the standard neuropathological rules for Alzheimer's illness (Karanth et al., 2020). Only 31% of patients have Advertisement pathology, 22% of AD pathology in addition to - synuclein pathology (Lewy bodies outside the brainstem), 29.5 percent had AD pathology in addition to TDP43 pathology (TDP43 incorporations in hippocampi), and 17.5 percent had AD pathology in addition to both - syncline and TDP43 pathology. Somewhere in the range of 29 and 52 percent of individuals in every one of these neurotically described classifications had something like one infarct (microinfarct, lacunar infarct, or enormous infarct) (Karanth et al., 2020). By 2050, the global incidence of dementia is anticipated to ascend from 50 million persons in 2010 to 113 million (Henry et al., 2011). Because of increased life expectancy, the commonness of dementia has grown in both major league salary and center/low-pay nations during the last 50 years. In certain high-income nations, such as the United States, the United Kingdom, and France, the prevalence of dementia has declined modestly (Yu-Tzu et al., 2017). In theFramingham Heart Study, for example, the age-changed and sex-changed riskriskfor occurrence dementia in those over 60 was 3.6 per 100people in the last part of the 1970sand early 1980s,be that as it may, 2.2 per 100 individuals by the last part of the 2000s and mid-2010s. The fact that those born more recently have a reduced prevalence of dementia might be attributable to educational, socioeconomic, healthcare, and lifestyle improvements that have happened during the last several decades.More grounded instructive achievement, specifically, has all the earmarks of being a defensive component against dementia, possibly because it reflects a greater ability to endure the effects of neurodegenerative and cerebrovascular illness (referred to as "cognitive resilience")(Yaakov,2012). Attempts to show cause-and-effect links between the numerous mitigating variables and dementia incidence, on the other hand, have been problematic. Although one neuropathological investigation indicated a tendency for a 24 percent fall in the brain A load from 1972 to 2006 in a cohort of 1,599 individuals with a typical age of 82 years, the reduction in dementia prevalence cannot be directly linked to AD(Kovari et al., 2014).

The frequency of overt cognitive decline increases considerably as people get older.Dementia risk increments decisively at 65 years old and keeps on moving after that. Dementia due to any cause affects around one out of every 100 persons aged 65–70, and four out of every 100 people aged 80–90.(Niu et al., 2016). The examination done by 20 experts from Europe and North America, the incidence of clinically diagnosed amnestic dementia (dementia without

biomarkers of Alzheimer's disease) increased from 1% in people aged 65–69 to7-8% in individuals matured 80-84 to 27% in those matured 90-94 (Hy and Keller, 2000). At any given age, the incidence of MCI is around double that of dementia (Gillis et al., 2019). As per studies utilizing MRI and PET to determine the weight of AD, MCI with AD pathology represents almost half of all occasions of MCI (Ronald etal. 2013). Alzheimer's sickness-related dementia represents 60-90% of all dementia cases(Elisabeth et al., 2016) as shown in figure 1.



Figure 1: An overview of Alzheimer's disease.

Aetiologies, like cerebrovascular illness and Lewy body, may have a role in up to half of those suffering from Alzheimer's disease (John et al., 2018). In big league salary nations, the most seasoned bunch (those over 90 years old) fastest-growing, furthermore, it likewise has the biggest gamble of mental impedance. In low- and middle-income countries11, increasing survival into older adulthood is causing a rise in the total societal burden of dementia.In high-income nations, the occurrence of dementia has been broadly explored, yet have low-and center pay nations, the circumstance is less clear. According to preliminary estimates, dementia is a global disorder with minimal difference in age-specific prevalence between areas (Martin et al., 2016). In one meta-analysis of 16 investigations, the prevalence of subjective cognitive problems was found to be 25% globally, however individual estimates ranged from 6% to 53% (37). suggesting that perceived cognitive decline is characterized

differently in different parts of the world and across cultures. the commonness of MCI changes with age, with 6.7 percent in those matured 60-64 years and 25.2 percent in those matured 80-84 years, like dementia (Ronald et al., 2017).

3. Pathophysiology

Alzheimer's disease (AD) is a synaptic dysfunction condition characterized by failures of molecular, cellular, and macro-scale cortical circuitry systems, with a preference for a cognitively eloquent brain. Synaptic pathophysiology is a compelling issue for tying together genetics, cell biology, neuropathology, and clinical aspects of Alzheimer's disease as shown in figure 2. Positive ('overt') lesions that can be seen by microscopies, for example, tau-containing neurofibrillary tangles, Aβ-containing plaques, enacted glia, or extended endosomes, are all examples of AD pathology. Negative ('covert') events, such asthe deficiency of synaptic homeostasis, neurons, orbrain network trustworthiness, can also be seen as part of AD.biochemistryof amyloid forerunner protein and tau protein is discussed extensively in Primer, their seeming importance as represented in the amyloid cascade theory is not(Todde et al., 2018).The pathology of sanctioned AD dementia incorporates Aβ-containing extracellular neuritic plaques that are found all through the cerebral cortex, as well as tau-containing neurofibrillary tangles that begin in the average worldly flap and progress to the fleeting, parietal, and front-facing projection isocortical areas (Arnold et al., 1991; Montine et al., 2012). APP peptides are made up of Aβ peptides (Christian and Dennis, 2007). After beta-secretases and alpha-secretase cleavage of APP (known as the amyloidogenic pathway)(Holtzman et al., 2011; Thinakaran and Koo,2008). The most common Aβ species have a length of 27–43 amino acids. Aβ is delivered as a monomer into the extracellular space after creation. Aβ (especially A42) has a strong propensity to aggregate due to its sequence, which happens in a concentration-dependent way. In the amyloidogenic process, additional molecules such as APPs, CTF, and AICD are produced in addition to Aβ. Cleavage of APP by α-secretase makes APPs and CTF while preventing the formation of Aβ; CTF is appropriately cut off into p3 and AICD by β-secretase. Although all cells make A, synaptic activity generates large amounts of it, and synaptic activity regulates its generation and release (Cirrito et al., 2005). The sleep-wake cycle 51 also influences Aβ levels. During wakefulness, Aβ synthesis and release into the extracellular space are greater, while Aβ clearance through the glymphatic system is higher(Earinand. Jeffery, 2017). Oligomeric Aβcooperates with metabotropic glutamate receptor 5 and NMDA receptors, supporting the concept that Aβ, particularly in its oligomeric form, is hazardous(Spires and

Bradely, 2014; Eduardo, 2018). It appears to speak with the 7 nicotinic acetylcholine receptors and insulin receptors, among others. Aβ appears cause obsessive changes in dendritic spines as well as synaptic adequacy. Albeit totaled Aβ is the clear sore that can actuate neurotoxicity, dysregulated APP handling can potentially affect synaptic function subtly. The consequences of APP cleavage play typical physiological parts. Applications, for instance, are a ligand for a GABA receptor subtype that influences synaptic transmission (Heather et al., 2019). Other cleavage items, like APPs and APPs, have cell receptors, demonstrating that they might influence synaptic action as well(Ulrike et al., 2017) non-AβAPP segments, such as C-terminal APP pieces(Scott and Gregory, 2020).

Tau is a protein that is for the most part found in the cytoplasm of axons and is connected with microtubules(Akihiko etal., 2019). It is related to the nuclear film and is accessible in both the presynaptic and postsynaptic compartments (Amy et al., 2014; Bahareh et al., 2018). Tau contains six isoforms because of grafting contrasts in exons 2, 3, and 10; the 3R and 4R isoforms are named after the presence of three or four microtubule -restricting spaces, separately (Yamada et al., 2014). A blend of 3R and 4R tau species is perceived in Alzheimer's disease. Tau's principal function is microtubule stability (Amy et al., 2014; Bahareh etal., 2018). Tau is leaned to post-translational changes and complete game plan. Exactly when this happens, it becomes hyperphosphorylated and gathers in cell bodies and dendrites. Tau is passed into the extracellular region on through synaptic enactment (Yamada.,et al., 2014;Jessica et al., 2016). It's consumed by postsynaptic neurons and glia (Collignon et al., 2012).



Figure 2: The pathophysiology of Alzheimer's disease.

Different post-translational adjustments of tau could permit it to be taken up distinctively in postsynaptic neurons or glia handled contrastingly or ended diversely or trigger cultivating accumulation. Besides, tau post-translational changes impact the speed of Alzheimer's illness advancement(Simon et al., 2020). ApoE has been linked to a variety of diseases(Yang et al., 2017) TREM2 as well as microglia. Although the mechanisms linking putative microglial activation to tau toxicity are unclear, they play a significant role in tau-mediated neurodegeneration(Ynag et al., 2019).

Intracellular tau totals, neuropil strings (tau parts in the neuropil), and dystrophic neurites are instances of neurofibrillary tangles (tau-containing deteriorated axons and dendrites encompassing A plaques) are histological indications of accumulated 3R and 4R tau. Albeit these designs can be seen in some brainstem cores in youthful grown-ups, they are absent in every one of them (HeikoBaark et al., 2011). The first location of cognition-related tauopathy is in the medial temporal lobe(64-65). Independent of A pathology, medial temporal tauopathy can develop (Prince and Morris, 1999; Delacourte, 2002). Medial temporal tauopathy occurs in some patients who never have Aβ elevations (John et al., 2014). Tauopathy of the AD kind, then again, progresses outside the average fleeting flap solely in patients with higher mind Aβ (Clifford et al., 2019; Rik et al., 2016). Area explicit mental issues bringing about MCI and dementia mirror the progressive movement of tau collection from the average fleeting projection to connected transient, parietal, and forward looking alliance cortices (Rik et al., 2016;Graff et al., 2021).

Apolipoprotein E (ApoE) lies at the crossing point of clinical, hereditary, and cell robotic components of Alzheimer's sickness (AD). The APOE quality encodes the ApoE protein, which is conveyed for the most part by astrocytes and started microglia in the brain. ApoE2, ApoE3, and ApoE4 are three prevalent isoforms in humans that differ simply by a solitary amino corrosive at position 112 or 158(Kim et al., 2009).The APOE 4 allele builds the gamble of Alzheimer's sickness dementia in a portion subordinate way. ApoE might impact AD risk in an assortment of ways, one of which is changing the start of Aβ total in the mind by altering the freedom and cultivating of Aβ (Tien-Phat et al., 2017). The three ApoE isoforms impact Aβ freedom and cultivating to various degrees, with ApoE4 for the most part affecting leeway easing back, trailed by ApoE3 and ApoE2(Tien-Phat et al., 2017). As a result, APOE 4 carriage can lead to early A buildup in a dose-dependent manner before clinical symptoms appear(Reiman et al., 2009). By the age of 57, around 10% of APOE 4

carriers had increased A (as measured by A-PET), whereas APOE e4 non-carriers had increased Aβ about 7 years later(Clifford et al., 2015). The particular processes by which A/APP and tau interact are unknown(Rik et al., 2019;Aureland Brdley,2020). Transgenic mice with Aβ-overexpression and wild-type tau develop either no tauopathy or a tauopathy that is unrelated to Alzheimer's disease(Kurt et al., 2003;Ricky et al., 2001.). There are interactions between A and tau in transgenic mice with both APP and tau mutations(AurelandBradely,2020). However, it is unclear if this model system can duplicate actual Alzheimer's disease. Aβ/APP, tau, and ApoE may interact in numerous cellular systems, according to theory: a synapses(Tara and Bradely,2014) microglia in microglia(82) in the endosomal, lysosomal, and proteasomal systems(Scott et al., 2017;Nixon and Dun-Sheng, 2011).

4.Mechanism of Alzheimer's Diseases

4.1β-Amyloid

Alzheimer's sickness is depicted by cerebral plaques containing β-amyloid peptide (Aβ) and dystrophic neurites in neocortical terminal fields, as well as significant neurofibrillary tangles in the average worldly flap Neuronal and white matter misfortune, as well as congophilic (amyloid) angiopathy, irritation, and oxidative harm, are available. Peptides are normally metabolic items comprised of 36 to 43 amino acids. Aβ40 monomers are far more common than the aggregation-prone and harmful Aβ42 species. The enzymatic activities of beta-site amyloid antecedent protein-dividing chemical 1 (BACE-1), a β-secretase, and α-secretase, a protein complex containing presenilin 1 at its reactant center on the amyloid forerunner protein, make - amyloid peptides (Christian,2007).Aβ gathers because of a lopsidedness among union and leeway, as well as peptide total, and this abundance might be the beginning of Alzheimer's infection. The "amyloid hypothesis" is based on research into hereditary types of Alzheimer's disease, such as Down's syndrome(Busciglio et al., 2002). Aβ42 is harmful to cells, according to data. (Dennis,2001;TanziandBertram,2005). The oligomers (2 to 6 peptides) in one type merge into intermediate assemblies in the other(R.Kayed,2003;Klein,L.William, et al.2001). Fibrils of -amyloid may form insoluble fibers in advanced amyloid plaques, which organize themselves into -pleated sheets.The most harmful types of Aβ are solvent oligomers and transitional amyloids (WashandSelkoe,2007). Dimers and trimers of Aβ are harmful to synapses in brain-slice preparations(Walsh, 2005;Klyubin et al., 2008). The degree of cognitive impairment in Alzheimer's disease is related to the number of oligomers in the brain rather than the overall amount of Aβ(Lih-Fen

et al., 1999). Aβ secretion at the synapse rises fast when neurons are activated, a process linked to the normal release of vesicles holding neurotransmitters. Synaptic Aβ at physiological levels could diminish excitatory transmission and prevent neuronal restlessness (Kamenetz et al., 2003).The proteases neprilysin and insulin-corrupting impetus control Aβ levels in a steady state as shown in figure 3.

Aβ monomers and oligomers are debased by Neprilysin, a layer moored zinc endopeptidase(Kanemitsu et al., 2003). The buildup of cerebral Aβ is caused by a decrease in neprilysin(Iwata,2001).The insulin-degrading enzyme, also known as thiolmetalloendopeptidase, is a thiol-metalloendopeptidase that obliterates short peptides like insulin and monomeric Aβ (Qiu,1998).The removal of an insulin-debasing chemical in mice brings down Aβdegradation by the greater part (Farris et al., 2003). Overexpression of neprilysin, an insulin-corrupting chemical, then again, diminishes plaque improvement (Leissring et al., 2003).



Figure 3: The mechanism of the Alzheimer's disease.

4.2. Tau

Alzheimer's disease and kindred tauopathies are characterized by neurofibrillary tangles, which are filamentous inclusions in a pyramidal neuron(Virginia et al., 2001).How much neurofibrillary tangle is a pathologic trait of Alzheimer's tainting reality. An unnecessarily hyperphosphorylated and totaled rendition of tau is the fundamental part of the knot.Tau, a soluble protein found in abundance in axons, upholds microtubule development and strength, as well as vesicle travel.Tau that has been hyperphosphorylated is insoluble, has no tendency for microtubules, and designs matched helical fiber plans. The degree of tau phosphorylation is controlled by enzymes that add and remove phosphate residues(Iqbabl et al., 2005). Moderate totals of atypical tau atoms, as Aβ oligomers, are cytotoxic(Khlistunova,2005). As well as impede cognition(Santacruz, 2005; Oddo et al., 2006). However, because changes in axonal transit and neuron number are independent of a load of neurofibrillary tangles, insoluble helical filaments may be inactive(Andorfer,Cathy et.al.2003). The hazardous intermediate tau species are sequestered by these helical filaments, a mechanism that may be protective(Hyoung-gon et al., 2005).In frontotemporal dementia with Parkinsonism, more than 30 Tau changes on chromosome 17 have been found. In Alzheimer's disease, however, Tau mutations do not occur, and neuron loss is out of proportion to the number of neurofibrillary tangles(Gomez-lisla et al., 1997). Increased levels of phosphorylated and total tau in the cerebrospinal fluid, however, are linked to worse performance on cognitive tests (Wallin et.al.2006).In individuals with moderate cognitive impairment, raised levels of the phosphatase amino acids T181, T231, and complete tau in the CSF liquid structure a biomarker test with phenomenal exactness for anticipating the beginning of Alzheimer's infection (Niklas, 2009). The buildup of Aβ seems to precede and promote tau aggregation, according to experimental findingsOddo, et al., 2003;Lewis,2001). Furthermore, A-induced degradation of cultured neurons and cognitive abnormalities in Alzheimer's disease-like mice necessitate endogenous tau in the presence of endogenous tau(Roberson et al., 2007; Rapoport et al., 2002). Extended oxidative tension, the thwarted protein-falling limit of the endoplasmic reticulum, and a proteasome deficiency The buildup of amyloid and tau proteins in Alzheimer's disease are accelerated by -mediated andautophagic-interceded freedom of harmed proteins, which are all connected with aging(Salon et al., 2000; Hoozemans, 2005). There are no medications that can switch these changes, albeit little atom inhibitors of -amyloid (e.g., scylloinositol) (NCT00568776) and tau oxidation and total. Grape seed polyphenolic extracts (e.g., resveratrol), which trigger aging-suppressor genes, are also promising medicinal agents(k,Ono, et.al.2008).

4.3 Synaptic Failure

Alzheimer's sickness might be to a great extent a synaptic disappointment disease(Selkoe,2002). In individuals with moderate cognitive impairment (a limited cognitive deficiency that commonly precedes dementia), hippocampal synapses begin to deteriorate, while surviving synaptic profiles exhibit compensatory increases in size(Scheff et al., 2007). Synaptophysin, a protein found in presynaptic vesicles, is reduced by roughly 25% in moderate Alzheimer's disease(Masliahet al., 20001).Neurotransmitters are lost excessively to neurons as the sickness advances,furthermore, this disaster is the most grounded mark of dementia (Dekosky and Scheff, 1990;Davies et al., 1987). Synaptic loss occurs as a result of aging(Eliezer et al., 2006). This has a strong impact on the hippocampus's dentate area(James et al., 2009). In plaque-bearing animals with Alzheimer's disease and after the Aβ peptide has been administered to brain slices, the basal transmission of single impulses and "long-term potentiation," an experimental indication of memory formation at synapses, are disrupted(Larson et al., 1999). Signaling molecules that are critical for memory are suppressed after this impairment. Presynaptic brain association discharge and postsynaptic glutamate receptor particle streams are disturbed (Karen et al., 1999; Shankar et al., 2007).Endocytosis of N-methyl-D-aspartate (NMDA) surface receptors causes a portion of the side effects (Eric et al., 2005).After a high-frequency stimulus train, the latter decreases synaptic activity even more by generating a long-term drop in currents.Typical maturing causes a comparable change yet to be determined among potentiation and wretchedness in neurotransmitters. These synaptic impairments can be triggered even early by intraneuronal Aβ (Lennartetal., 2000).

4.4 Depletion OF NeurotrophinANDNeurotransmitters

Neurotrophins help neurons and glia proliferate, differentiate, and survive, and they also play a role in learning, memory, and behavior. In late-stage Alzheimer's disease, the typically high numbers of neurotrophin receptors on cholinergic neurons in the basal forebrain are substantially diminished (Fig. 3). In animal models, nerve growth factors can help to save basal neurons(Copper et al., 2001).What's more, a stage 1 investigation of the NGF quality in Alzheimer's sickness patients exhibited upgrades in discernment and mind digestion (Tuszynski et al., 2015). Mind inferred neurotrophic factor (BDNF), a neurotrophin relative, is drained in Alzheimer's sickness and moderate mental hindrance (Connor et al., 1997). Aβ42 oligomers were used to replicate this discovery in the lab(Garzon andFahnestock) as shown in figure 4.



Figure 4: Biological alteration in Alzheimer's disease.

Treatment with BDNF improves neuronal survival, synapse function, and memory in rats and nonhuman primates(Ernfors and Bramham,2003). It is shown that BDNF substitution may be a treatment choice for Alzheimer's infection (Nagahara et al., 2009).The gathering of Aβ and tau has been connected with an absence of cholinergic projections in Alzheimer's infection. Presynaptic nicotinic acetylcholine (7 nicotinic acetylcholine) for intellectual ability, receptors are required. handling and their levels ascend in Alzheimer's sickness (Milos et al., 2009). Aβ interacts with -7 nicotinic acetylcholine receptors, decreasing acetylcholine release and long-term potentiation maintenance, according to experiments(Wang,2000).The amount of muscarinic acetylcholine receptors, or receptor coupling, is reduced in Alzheimer's infection patients' frontal cortexes. Protein kinase C is activated by pharmacological activation of the postsynaptic muscarinic type 1 (M1) acetylcholine receptors, leaning toward the handling of amyloid forerunner protein that doesn't create amyloid (Nitsch, 1996).Additionally, tau phosphorylation is limited when nicotinic acetylcholine receptors or M1 receptors are incited (Antonella et al., 2006;Bitners,2009).Cholinesterase inhibitors increase neurotransmission and give mild palliative relief in Alzheimer's disease, but their effectivenesswears off with time. The utilization of agonists and modulators of nicotinic acetylcholine receptors - 7 is being inspected.Particular M1 agonists have been demonstrated to upgrade comprehension in clinical investigations(Bodick et al., 1997).Aβ levels in the

cerebral liquid were brought down, also (Hock et al., 2000). However, these substances are poisonous.

4.5 Mitochondrial Dysfunction

Aβ is the area of strength for a toxin that impacts the synaptic pool explicitly(Mungarro-Menchaca et al., 2000).Exposure to Aβ inhibits critical mitochondrial enzymes in the brain and isolated mitochondria in Alzheimer's disease(Hauptmann et al., 2006; Reddy and Beal,2008). The enzyme cytochrome c oxidase is targeted(Caspersen, 2005).Electron transport, ATP amalgamation, oxygen utilization, and mitochondrial film potential are completely impacted subsequently.Oxidative stress, cytochrome c delivery, and apoptosis are completely brought about by an expansion in mitochondrial superoxide revolutionary creation and change to hydrogen peroxide. The increase of Aβ in structurally damaged mitochondria isolated from Alzheimer's disease patients' brains(Hirai et al., 2001).as well as transgenic brains(Caspersen,2005).Other evidence of intraneuronal Aβ in Alzheimer's disease supports this theory(Gouras et al., 2005). Aβ mitochondrial confining target of Aβ is alcohol dehydrogenase (Lubstbader,2004). Normal cells repopulated with mitochondrial DNA (mtDNA) from people with sporadic Alzheimer's disease show similar alterations(Cardoso et al., 2004).mtDNA maintains high levels of oxidative stress in both Alzheimer's disease and the normal aging process damage(Hirai et al., 2001). Because the mitochondrial genome of the brain is unstable and irreparable, mtDNA mutations accumulate throughout time(Wallace,199). In Alzheimer's dementia, mitochondrial discontinuity (or parting) brought about by the oxidation of a dynamin-like carrier protein might bring about neurotransmitter misfortune (Cho et al., 2009). In people with gentle to-direct Alzheimer's illness, the allergy medicine dimebolin hydrochloride, a thought mitochondrial energizer, has been displayed to upgrade discernment and conduct (Doody et al., 2008).

4.6 Oxidative Stress

Broken mitochondria make oxidizing free revolutionaries, which cause critical oxidative pressure in Alzheimer's illness and the typical maturing mind.Experimental models reveal that oxidative damage signals appear before pathogenic alterations(Akihiko et al., 2001). Aβis a powerful reactive oxygen species producer (Hensely et al., 1994).and reactive nitrogen species (Colinetal.2001).is a major source of this harm. A's pro-oxidant actions on neuronal, microglial, and cerebrovascular cells are mediated through the receptor for advanced glycation end products(Shi et al., 1996). Mitochondrial hydrogen peroxide quickly diffuses

into the cytoplasm to participate in hydroxyl radical production catalyzed by metal ions. The very diffusible nitric oxide extremist is delivered by invigorated microglia.Several atomic targets are injured by these responsive oxygen and nitrogen species. Toxic aldehydes are conveyed when film lipids are peroxidized(Keller et al., 1997).Can wreak havoc on vital mitochondrial enzymes(Alien et al., 2001;Kenneth and Luke, 1998). Other important proteins are oxidized directly, resulting in carbonyl and nitrated derivatives(Mark et.al.1997).Expansions in layer penetrability to calcium, other ionic awkward nature, and diminished glucose transport came about accordingly (Robert et al., 1997).make the energy imbalance worse. In multiple ways, increased amounts of free divalent transition metal ions (iron, copper, and zinc) and aluminum are connected to reactive oxygen species-mediated damage and neurodegeneration(Lovell et al., 1998; Craft et al., 1998). These metal ions also increase tau aggregation and conformational or phosphorylation alterations(Yamamoto et al., 2002).Zinc, which is commonly assumed to be a toxin in Alzheimer's disease, may protect cells by inhibiting A channels in lower quantities(Arispe et al., 1996).or fight for A binding with copper(Cuajungco and Fget,2003).Although animal models and the majority of cross-sectional research in aging populations suggest a link between antioxidant consumption and cognitive performance, randomized cell reinforcement preliminaries have to a great extent fizzled (Pratico et al., 2008).Since basic catalysts depend on coordination with divalent metals, helpful chelation of these metals may be perilous. PBT2, a protected medication got from clioquinol that weakens metal proteins, was tried in a pilot stage 2 review (NCT00471211) (Lannfelt et al., 2008). It exhibited some efficacy.

4.7 Inflammation

In the cerebrums of patients, initiated microglia and responsive astrocytes are seen in fibrillar plaques, and their biochemical markers are improved by Alzheimer's infection (AD)(Coray-Wyss and Mucke, 2002). The phagocytic microgliaengulfand destroy A at first. On the other hand, Chronically activated microglia activated microglia, release chemokines and a cascade of harmful cytokines, including interleukin-1, interleukin-6, and growth putrefaction factor (TNF-α) (Akiyama et al., 2000). Microglia, as vascular cells, have receptors for the state of the art glycation completed results, which tie Aβ and increase the production of cytokines, glutamate, and nitric oxide (Shi et al., 1996;Yuekui et al., 2001). Chemokines have been shown in investigations to stimulate the migration of monocytes from the peripheral circulation into plaque-bearing brain tissue(Simard et al., 2006).The traditional complement pathway is also stimulated by fibrillar Aβ and glial activation(Macgreeet et al.,

2001).Supplement cleavage items C1q and C5b-9 are found in tangles and plaques, showing that opsonization and autolytic attack are happening (Akiyama et al., 2000).Unprecedented stage reactants, for example, alpha1-antichymotrypsin,alpha2-macroglobulin, and C-responsive protein are conveyed by empowered astroglia and can both decay and reduce Alzheimer's affliction. But provocative (and oxidative) events have been associated with a break of the vascular blood-mind prevention in Alzheimer's affliction, it's not clear if this results in monocyte or amyloid inflow from the bloodstream in individuals(Yasuko et al., 2007;Clifford et al., 2007).



Figure 5: An overview process of inflammatory markers, oxidative stress amrkes and biomarkers in Alzheimer's disease.

Treatment is complicated by microglia's dual responsibilities of removing Aβ and producing pro-inflammatory chemicals(Milan et al., 2005). Nonsteroidal anti-inflammatory drugs have been shown in prospective observational studies to reduce the risk of Alzheimer's disease and halt its development(Mcgeer, 2007; Vlad et al., 2008). Selective decrease of Aβ42 is one of their modes of action(Alberto et al., 2004; Weggen, 2003). Hiding of cyclooxygenase-2 or the prostaglandin E2 receptor, microglial phagocytosis stimulation, and PPAR-γ activation Randomized studies of nonsteroidal anti-inflammatory drugs have recently been conducted(Szekely et al., 2008). An investigation of a subordinate, tarenflurbil (Flurizan)

(NCT00105547), tracked down no sign of deferring mental deterioration or bringing down the gamble of Alzheimer's infection. Various TNF-α and complement factor blockers, as well as medicines that stimulate phagocytosis, are being studied in addition to the Aβ- vaccination efforts(Shen,et al., 2003).

5. Etiology of Alzheimer's disease

5.1.Aging

In everybody, maturing is the main source of Alzheimer's illness.A new report has uncovered two potential maturing processes that might play a part in the advancement of Alzheimer's sickness. One is the possibility that free revolutionaries (responsive oxygen) are unsafe. The species created during cell breath might play a part. A significant part in the aging and development of the body during the year AD(Smith et al., 1995). There is a lot of evidence that oxidative damage to proteins and membrane lipids, as well as overexpression of antioxidant enzymes, are associated with Alzheimer's contamination(Sayre et al.,1997; Smith et al., 1997). At least in part, the harmful effects of β-amyloid are mediated by the peptide's production of free radicals(Hensley et al., 1994;Harris et al., 1995).Since iron might animate the production of destructive free revolutionaries, the new revelation of redox-dynamic iron stores connected with decrepit plaques and neurofibrillary tangles is critical in such a manner (Smith et al., 1997). Furthermore, a team of researchers from the University of British Columbia discovered that people with Alzheimer's disease have higher blood levels of the iron-binding protein melanotransferrin, indicating that the brains of those with AD may have abnormal iron management(Malcolm et al., 1996 In the event that the early preliminaries are imitated, melanotransferrin levels in serum might end up being an important analytic assistant. The possibility that oxidative harm is a critical component in maturing has prompted an enormous scope of clinical review utilizing vitamin E (α-tocopherol) in patients with moderate to outrageous Alzheimer's infection (Marry et al., 1997). Although a daily dose of 2000 IU of vitamin E delayed the advancement of the disease, there was no evidence that vitamin E therapy was related to clinical relief or reversal of disease symptoms. It's critical to note that the redox balance in the brain is complicated and that more comprehensive treatment options focused on reducing disease-related pathways will be necessary. The messenger RNA is another proposed aging process; mutations in messenger RNA have been seen in senior people and older rats (Van-Leeuwen, 1998). A reading frame is changed when two consecutive bases in a protein are deleted, resulting in a protein with an amino acid sequence that differs from that specified in the original gene. The expected

aberrant forms of two proteins involved in the etiology of Alzheimer's disease, β-amyloid precursor protein, and ubiquitin- B, as well as their corresponding altered messenger RNA, were detected in the brains of patients with AD but not in controls(Van-Leeuwen, 1998).

5.2 Environmental factors

The revelation that monozygotic twins may not get Alzheimer's sickness simultaneously(Rapoport et al., 1991). shows that environmental variables have a role in the onset of Alzheimer's disease. One hypothesis is that Alzheimer's sickness is an ongoing, dynamic fiery condition. Mild active inflammation, involving microglial and complement activation, as well as the presence of inflammatory cytokines, can be seen in the brains of Alzheimer's patients (Mcgeer and Mcgeer, 1995). Furthermore, in aged people, the recruitment and activation of microglia are linked to plaque development(Mackenzie and Miller, 1994). Although the inflammation is most likely related to more basic injuries, it may play a role in a morbid cycle of tissue destruction, similar to rheumatoid arthritis. Epidemiological retrospective studies have been undertaken to estimate the likelihood of getting Alzheimer's disease in people who take anti-inflammatory medicines or who have illnesses like rheumatoid arthritis, where these treatments are often used. Over 21 such assessments, including the Canadian Study of Health and Aging, have been coordinated. Although these findings are not uniform, have observed a lower prevalence of AD among people taking anti-inflammatory drugs on a long-term basis(Mcgeer et al., 1996). According to the findings, acetaminophen, pain medication with no anti-inflammatory effect, is not linked to Alzheimer's disease. The findings of a study of divergent twins in which the use of anti-inflammatory medicines was the sole factor that differed among burdened and unaffected individuals from the twin matches are maybe the best-supporting proof yet (John et al., 1995 On the off chance that nonsteroidal calming drugs (NSAIDs) make a preventive difference, the instrument of activity is obscure; elderly patients on chronic high doses of NSAIDs show a significant reduction in activated microglial cell density but no difference in the number and density of plaques and tangles when compared to those who do not take NSAIDs(Mackenzie and Munoz, 1998). Because most epidemiological data is retrospective, it's difficult to say which anti-inflammatory medicines are helpful, at what doses, and for how long.

Some research focused solely on NSAIDs, whereas others used steroids as well. Excessively far, just a single twofold visually impaired, randomized, fake treatment controlled investigation of indomethacin has been distributed; it looked at the effects of indomethacin

on cognitive and functional outcome measures in individuals with Alzheimer's disease over six months(Rogers et al., 1993). However, because long-term use of NSAIDs is linked with considerable adverse effects in the elderly, the study's good results must be confirmed in larger-scale studies before they can be widely adopted. Ladies on estrogen substitution medicine might be more averse to being determined to have Alzheimer's infection, as indicated by numerous epidemiological investigations (Henderson, 1997; Kawas, 1997). A few tiny studies show that estrogen treatment improves the symptoms of female Alzheimer's sufferers. Estrogen's extensive effects on the brain(Birge, 1997). Albeit the cycles have not been made sense of, these discoveries are practical. Preliminary evidence suggests that using estrogen and tacrine, a cholinesterase inhibitor, together may improve treatment effectiveness (Schneider et al., 1996). The way that estrogen substitution treatment might raise the gamble of bosom and endometrial malignant growth highlights the requirement for corroborative huge scope, randomized clinical investigations before postmenopausal ladies are treated with estrogen (Shapiro et al., 1985;Colditz et al., 1995). It's worth noting that estrogen replacement medication hasn't been linked to a lower risk of Alzheimer's disease in certain research(Brener et al., 1994; Sally et al., 1997). Throughout recent years, clinicopathological relationship examinations have uncovered that, though all patients with serious AD-type injuries had dementia, people with gentle sores might have. The Nun study's discoveries gave a huge understanding (Snowdon et al., 1997). For individuals with AD-type lesions, the presence of brain infarcts, even if mild and infrequent, increased the risk of dementia by up to 20 times. Because infarcts in the absence of AD-type lesions exhibited limited cognitive consequences, this might be the most prevalent route by which vascular injuries lead to dementia (Snowdon et al., 1997). Others have similarly verified the same findings(Jellinger, 2013). As a result, aggressive treatment of hypertension and other vascular risk factors, as well as the promotion of a balanced diet and exercise, may help to lower the risk of dementia.

5.3 Metals

Aluminum was almost the sole metal included in previous evaluations as a risk factor for Alzheimer's disease, and its exposure was and is still contentious(Armstrong, 2013; Armstrong, et al., 1995). Metal exposure has been a growing source of worry since the 1980s, because the capacity of cells to properly sustain important functions as they age, such as energy production, repair, and what's more, recovery, is reliant upon an assortment of metals (Blaine et al., 2012). Furthermore, a large percentage of the population is constantly exposed to trace metals such as aluminum, lead, iron, and copper, which can emerge out of a few

sources and are conceivable gamble factors for Alzheimer's illness (Heng-Wei et al., 2018). However, found no link between metal accumulation and age or neurodegeneration, indicating that the brain is not a good place for metal buildup.

According to recent data,a wide variety of metals might be involved in AD pathogenesis, there could be connections between them,also, metal awkwardness prompting cell homeostasis could be a vital job. In terms of particular metals, more recent research on aluminum has found that miners exposed to aluminum-rich dust had a much higher risk of developing Alzheimer's disease(Peters et al., 2013). implying that certain elements of this idea should be revisited Aside than aluminum (Wang et al., 2016).zinc(McCord and Alzenman, 2014). Mercury (Mutter, 2007). Copper(Heng-Wei et al., 2018; Pal et al., 2019)manganese (Du-Ke et al., 2017)cadmium (Notarachille et al., 2014).as well as magnesium(Veronese et al., 2015). These things have been associated with an extended bet of Alzheimer's disorder. A significant number of these metals have been shown to straightforwardly communicate with APP digestion or APOE (Mutter, 2007).The synergistic effects of a couple of metals have similarly been highlighted in examinations.Because raising APP and affecting the assistance of the amyloidogenic pathway, a blend of arsenic, cadmium, and lead improved Aβ testimony in the cerebrum and HC of adolescent rodents (Ashok et al., 2015). In a double transgenic mouse model, however, actual intakes of aluminum and zinc did not exacerbate AD-type pathology (APP, tau) (Harhiko et al., 2012). Metal homeostasis is a critical mechanism that becomes dysregulated with aging (Adlard et al., 2018). Lacks in key minor components, as well as openness to other metal particles, can prompt AD pathogenesis.In like manner, there is a breakdown of homeostasis among zinc, copper, and iron in AD plasma/serum and cerebrum, which are all involved in the guideline of APP/tau and associated with APOE (Xu-He et al., 2014).

5.4 Genetic

Despite difficulties in interpreting early studies of family cases, such as relatives' skewed recollection and the identity of the real illnesses implicated, there was reliable proof that first-degree family members of AD patients had a raised gamble of dementia themselves(Henderson et al., 1988). In an early investigation,it was stressed that the degree of the genetic relationship differed among people(Armstrong, 2019). They found that late-onset cases were no more likely than the general population to have a family history and that a large percentage of cases were unlikely to have a main genetic foundation.With regards to

Henderson(Henderson et al., 2019).The review was published, but there was no information on the individual genes that are thought to be implicated in Alzheimer's disease.As a result, a limited number of genes have been identified as causative, while many others have been identified as potential risk factors.

5.4.a. APP

During the 1990s, convincing evidence in regards to an association between a couple of noteworthy kinds of EO-FAD and explicit genetic variables emerged, with a set number of cases attached to APP quality changes(Chartier et al., 1991).The creation of a variety of A peptides occurs when APP is cleaved(Greenberg,1995).The most frequent is Ab1-42, which is mostly found in SP, whereas Ab1-40, which is more soluble, is also identified in conjunction with cerebral microvessels(Miller et al., 1993).and may appear later in the course of the disease (Delacourt et al., 2002). Furthermore, APP mutations in the Aβ coding region may result in Ab1-38 accumulation in vessel walls, especially in cases of severe cerebral amyloid angiopathy(CAA)(Gessel et al., 2012). It's also possible that early soluble peptide oligomers are involved(Hardy and Higins, 1992). They differ depending on the mutant type, giving a genetic foundation for FAD pathogenesis differences. The disclosure of Aβ prompted the advancement of the ACH (Chapuis et al., 2017).These characteristics integrate the 'ferritin family homolog 2 characteristics' (FERMT2),), a -3-integrin co-activator that is linked to differences in Aβ in the cerebral spinal fluid (CSF)(Chapuis et al., 2017).By expanding how mature an APP is and empowering its reusing at the phone surface, underexpression of this quality might raise Aβ. Moreover, the ATP-restricting tape carrier A1 (ABCA1) quality might assume a part in the Aβ statement and leeway, and it could be connected to some AD varieties (Radosveta et al.,2010).

5.4.b.PSEN1&2

Transformations in the PSEN1/2 qualities are connected to the most regular sort of EO-FAD (Sherrington et al., 1995).PSEN has contained nine transmembrane areas that are found on the endoplasmic reticulum.PSEN is isolated by endoproteolytic compounds and assembled into the γ-secretase complex, which is then moved to the cell surface, perhaps impacting APP dealing (Honarnejad et al., 2012).PSEN1 changes could interface with APP by extending 42 γ-express secretase cleavages of regular APP, leading to more Aβ deposits (Shinji et al., 1998).PSEN, on the other hand, might serve several additional purposes. It might work in two ways. In the first place, it could cause a deficiency of capacity by bringing down γ-secretase

movement (Wolfe, 2012).Second, the PSEN1 quality is believed to be engaged with indent flagging, which is critical for cell differentiation (Steiner, H, et.al.1999).PSEN1/2 might also be implicated if cellular calcium homeostasis is disrupted (Giancarlo et al., 2006).or in interactions with the transcriptional coactivatorcAMP-response element-binding (CREB-binding) protein, which is important for gene expression regulation (Bartolotti et al., 2016).Fourth, ephrin-B may facilitate PSEN1's neuroprotective activities (Gaelet al., 2013).furthermore, a misfortune in this insurance could play a part in Alzheimer's illness. Hence, there might be parts of PSEN1's action that are inconsequential to APP digestion.

5.4.c. Apolipoprotein

A couple of assessments have included the influence of cholesterol move characteristics, for instance, apolipoprotein E (APOE), apolipoprotein C1 (APOC1),and apolipoprotein J (APOJ) (clusterin) as risk factors for Alzheimer's disease, proposing a breakdown in cholesterol homeostasis(Valerie et al., 2010).People with AD had 2-3 times the recurrence of allele E4 contrasted with typical control cases, showing that allelic variety in the APOE quality is a significant gamble factor in SAD (Strittmatter et al., 1993). Moreover, the presence of E4 might straightforwardly affect mental capacity, since it has been linked to worse test results on adult memory and learning activities(Liu et al., 2014).Allele E4may hurry the beginning of Alzheimer's illness pathology in the maturing mind (Fumitaka et al., 1995).As a result, it's much of the time connected to the previous beginning of the disease (Gomez-Isla et al., 1996).The bulk of research also shows that those who express E^4 have more A deposition (Beffert and Poieier, 1996; Berr et al., 1994).Moreover, fringe aggravation, APOE, and Aβ may all cooperate to cause mental deterioration and cerebrovascular brokenness (Marottoli et al., 2017).E4 essentially upgrades age-subordinate CAA in transgenic mice (Fryer et al., 2003).

6. Types of Alzheimer’s disease

6.1 Early-onset of Alzheimer’s disease

Alzheimer's disease (AD) was once thought to be a neurodegenerative ailment that manifested in early adulthood or middle age, with onset before the age of 65. Extracellular amyloid-positive neuritic plaques and intracellular tau-positive neurofibrillary tangles in the mind of a 51-year -old woman with memory and language impairments and behavioral changes were first described by Alois Alzheimer in the brain of a 51-year-elderly person with memory and language weaknesses and conduct changes (Maurer et al., 1997).). In the last

part of the 1960s and mid-1970s, analysts underscored the presence of equivalent neuritic plaques and neurofibrillary tangles in more established dementia patients, refocusing Alzheimer's research on the substantially higher numbers of late-onset AD patients. Early-onset AD patients, while being overshadowed by late-onset AD, are not forgotten (about 5 percent to 6 percent of all those with AD) (Zhu et al., 2015).Clinical and neurobiological characteristics differ greatly, necessitating various therapeutic techniques. Some researchers believe that these distinctions are significant enough to distinguish separate types of illness (Mendez, 2019). Beginning stage AD is characterized as Alzheimer's sickness that grows clinically before the age of 65, and it is the most common reason for beginning stage neurodegenerative dementia (Harvey, 2019).Somewhere around 33% of individuals with youthful beginning dementia havea beginning stage Alzheimer's infection. The others are suffering from vascular cognitive impairment, frontotemporal dementia, drug-related illnesses, Lewy body disease, or autoimmune or viral diseases. Early-onset Alzheimer's disease has an annual incidence rate of around 6.3 per 100,000 people aged 45 to 64 (Bickel H., et al., 2006).with a prevalence incidence of around 24.2 per 100,000 (Edward et al., 2011).with 2006 evaluations of somewhere in the range of 220,000 and 640,000 people with early-phase AD in the United States. Indeed, even among this beginning stage populace, the possibility of fostering Alzheimer's sickness develops with age, with the number of occasions of beginning stage AD expanding dramatically as the time of beginning methodologies 65 (Lambert et al., 2014).

6.1.a.Clinical Features of EOAD

Alzheimer's infection (AD) that strikes early in life is known as beginning stage AD.First, early-onset Alzheimer's disease has a strong genetic component, with the direct autosomal dominant transmission in one subgroup and greater polygenic risk in general. Patients with an autosomal dominant family type of early-onset AD may have unusual clinical characteristics such as headaches, myoclonus, seizures, gait problems, pseudobulbar palsy, or hyperreflexia, as well as an elevated risk of AD in their families(Gerritsen et al., 2016; Joshi et al., 2012).Second, in early-onset AD, overall deterioration is quicker than in late-onset AD (not related to APOE) (Wattmo and Wallin, 2017).According to research,people with early-onset AD may have a more severe clinical course (Kodeam et al., 2008; Stanley & Walker, 2014). Patients with beginning stage AD had a higher mortality risk than those with late-onset AD after correcting for the direct effects of aging on mortality (Chang et al., 2017).Early-onset AD is responsible for a substantial percentage of premature deaths in those aged 40 to 64

(Moschetti et al., 2015).Early-onset AD is responsible for a substantial percentage of premature deaths in those aged 40 to 64 (Wattmo and Wallin, 2017; Van et al., 2013).Probably due to a missing or delayed diagnosis, or a more extensive diagnostic assessment (Eriksson et al., 2014).Fourth, as a risk factor for dementia, people with early-onset AD are more likely to have a history of traumatic brain injury (Mendez et al., 2015).Early-onset AD patients, on the other hand, had fewer cerebrovascular risk factors, circulatory issues, diabetes mellitus, and obesity than late-onset AD patients (Gerritsen et al., 2016; Kadohara et al., 2017).The general clinical profile of early-onset AD differs from that of late-onset AD, which is perhaps the most noteworthy difference. Rather than the typical amnestic condition found in late-onset AD, a large number of individuals with early-onset AD have linguistic, visuospatial, or dysexecutive characteristics (Palais et al., 2015). Patients with beginning stage AD had more grounded memory acknowledgment scores and semantic memory than patients with late-beginning AD, yet they have lower consideration, language, chief working, ideomotor praxis, and visuospatial capacities (Palais et al., 2015; Mendez, 2019).

6.2 Late-Onset OF Alzheimer's Diseases

This is the most common kind of dementia, which influences people matured 65 and up. Around 80% of people with Alzheimer's illness are beyond 75 2 years old, infection frequency ascending from 2 for every 1000 in the 65-74 age gatherings to 37 for each 1000 in the 85 or more age bunch. The quantity of people with Alzheimer's infection in the United States is supposed to be practically high pitch by 2050, with the 85 and more established age bunch representing most of the increment (Hebert et al., 2013).

6.2.a.Clinical features

The most well-known clinical highlights of late-beginning AD are the continuous beginning of momentary memory weakness, which advances more than quite a while to incorporate different parts of cognizance, like language disability, chief brokenness, and visuospatial debilitation, and ultimately influences the capacity to perform day to day exercises.Neglect, for example, failing to remember discussions, rehashing comments and inquiries, and losing individual effects, are normal early indications of late-beginning AD.

Long-term memory is still quite intact. In the beginning phases of Alzheimer's infection, a patient. The individual may know about their flashing mental deterioration and hold understanding. Later side effects might incorporate trouble finding words, challenges with

math, and memory issues.Subjective cognitive impairment is often the first sign of a problem. Patients may have memory loss while still performing well on tests. They are still able to do cognitive and neuropsychological tests at the bedside.to carry out the entirety of their everyday activities. Gentle mental debilitation (MCI) is the next level, in which a patient or informant has a cognitive complaint that may be detected on tests but is still able to adjust and conduct everyday tasks.MCI can be characterized as an anamnestic,non-amnestic, single space, or different areas (it is available to (rely upon whether memory disability). Emotional mental debilitation is the most well-known side effect of Alzheimer's sickness, trailed by amnestic single-space MCI, amnestic various area MCI, and gentle dementia. It is crucial to note, however, that not all patients will go through these stages in the same way. Dementia was shown to be 31.4 percent per year in those with amnestic MCI in a study of the elderly, compared to 8.4 percent per year in people with normal cognition (Peltz et al., 2011).The deficiency of autonomy in practical limits, for example, the powerlessness to deal with remedies, arrangements, transportation, or cash, happens when MCI advances to gentle dementia. Patients with Alzheimer's infection may just need help with instrumental exercises of everyday living (medicine the executives, funds, and transportation) right away, however as they progress through the phases of dementia, they will need support with additional essential exercises of day to day living, like dressing, washing, and prepping. They should be taken care of as their Alzheimer's sickness advances, and they will ultimately become incontinent. At last, patients might become quiet, incapable to swallow, and disabled in the end-stage.

7.Biomarkers of AD

Physiological, biochemical, or physical factors that might be assessed in vivo and distinguish specific neurotic modifications in infection are alluded to as biomarkers. As per the strategy of investigation, we might partition AD biomarkers into two classes: biochemical CSF biomarkers and imaging-chose biomarkers (Robb et al., 2016; Christian, 2016).

7.1.Cerebrospinal fluid biomarkers

Even though only neuropathological evidence can be used to make a definitive diagnosis of Alzheimer's disease, CSF indicators can help with the diagnosis of probable AD. Furthermore, abnormal biomarker levels in the CSF are believed to be dynamic sometime before the main side effects manifest. As a result, a lot of work has gone into proving that these biomarkers can identify preclinical Alzheimer's disease before

behavioral symptoms appear (Moghekar et al., 2013).In cognitively normal people, Aβ is generated in the brain and diffuses into the CSF, where it exists in moderate amounts with diverse forms. Aβ42 appears to be required for the initiation of Aβ aggregation in a variety of species and isviewed as a decent biomarker for Alzheimer's sickness. Nevertheless, in individuals with AD, the mean centralization of Aβ42 in the CSF is extensively lower than in age-matched controls, and this is negatively associated with Aβ load (Sunderland et al., 2003).Aβ42 can also be used as a diagnostic and surrogate biomarker for Aβ42 accumulation in the brain, according to relevant longitudinal CSF investigations (Roe et al.,2013). Expanded Aβ the weight has a little however nontrivial relationship with explicit spaces of mental execution in people who are right now intellectually typical, as indicated by a new meta-examination, inferring that Aβ42 can help recognize preclinical AD or create clinical result measures (Hadden et al.,2013).Low levels of Aβ42 also emerge early in the course of AD, and even earlier in patients who are still cognitively normal, several years before MCI (Schmand et al., 2010; Stomrud et al., 2007).Ongoing proof recommends that in those with inherited changes, a drop in CSF Aβ42 levels happens no less than 20 years before clinical dementia creates (Rigman et al., 2012).However, because Aβ42 may be seen in other dementias, it may be difficult to use Aβ42 alone to differentiate AD from other dementias. As a result, it ought to be utilized related to other biomarkers to foresee specific dementia.

CSF tau levels, unlike Aβ42, indicate the evolution of a tau-related disease in the cerebral cortex. Tau is high in the CSF of most Alzheimer's patients, reflecting neuronal death linked with the disease's physiopathological process (Leonardo et al., 2012).Tau rise likewise seems to happen in specific intellectually typical individuals, where its levels relate to how much amyloid statement and when joined with Aβ42, indicate cognitive impairment (Anne, 2009).In the same way that Aβ42 is less effective in the differential diagnosisof AD, outright tau (t-tau) level is less helpful in the differential investigation of AD.A bioassay of phosphorylated p- tau, on the other hand, has a sensitivity of 85 percent and explicitness of 97% in separating Alzheimer's sickness from other neurological ailments. These early discoveries suggest that p-tau is better than t-tau in distinctive conclusions, so making up for the absence of A42 and t-tau around here (Miroslaw et al., 2009; Yuan,Hu,).Furthermore, a drop in p-tau-181 appears to be linked to improved cognitive performance (Seppala et al., 2011).After Aβ42 aggregates and rises as amyloid accumulates, significant abnormalities in CSF t-tau and p-tau metabolism are expected to emerge (Buchhave, 2012).In human exploration, notwithstanding, there is as of now insufficient proof of this connection.

Additional longitudinal biomarker investigations with extensive clinical follow-up of non-demented persons are needed to offer more insights regarding this association. The default mode network (DMN), is a collection of linked brain regions that sustain vigorous metabolic activity while the brain is at rest (Jones et al., 2011).Recent research has found that reduced CSF Aβ42 and increased CSF phosphorylated tau both have an impact on DMN integrity in older persons with normal cognition (Wang et al., 2013).According to this research, combining CSF A42 with t-tau or p-tau can be used to predict development from cognitive normality to MCI/very mild dementia. Several robust studies show that the CSF tau/Aβ42 and p-tau/Aβ42 ratios are linked to an increased risk of cognitive decline in normal people, meaning that the CSF tau/Aβ42 ratio is a very excellent predictor of dementia during a 3 to 4 year period (Donata et al., 2012).Furthermore, as compared to biomarkers alone, the Aβ42/tau ratio had a higher sensitivity and specificity in diagnosing symptomatic AD and distinguishing it from frontotemporal dementia.(Irwin etal., 2013; Fagan, 2011).As a result, it appears that typical aged people with a high tau/Aβ42 ratio are those with the first stages of Alzheimer's disease.Furthermore, a growing body of research suggests that Alzheimer's disease is linked to changes in bioenergetics and mitochondrial activity (Swerdlow et al., 2010; Pinar et al., 2012).Neurons depend vigorously on mitochondria for oxygen-consuming energy, which contain many duplicates of their DNA (mtDNA). The covalently shut round state of mtDNA makes it more impervious to nuclease breakdown, making it bound to appear in the CSF.This intriguing trait prompts us to investigate if cell-free mtDNA may be detected in the CSF, whichcould show changes in mind digestion and act as an early sign of the neurodegenerative cycle in AD. Recent research backs up the idea that the decreased mtDNA concentration in CSF might be a new biomarker for detecting preclinical Alzheimer's disease (Podlesniy et al., 2013).More longitudinal examinations of CSF biomarker elements, especially in people in the preclinical phase of the disease, are required.Moreover, the pervasiveness of plaque-subordinate irritation in Alzheimer's infection has been irrefutable in both human and transgenic models of the sickness. In addition, various inflammatory markers have been proposed as AD biomarkers in the past (Mrak et al., 2006).Middle people that are expanded during the underlying phases of the oligomeric-prompted fiery interaction in AD minds would be reasonable early analytic pointers.

A network metalloproteinase 9 is a promising choice in such a manner (MMP-9). MMP-9, an individual from the Zn2+-containing and Ca2+-requiring endoprotease family, is engaged with typical tissue rebuilding During inflammatory processes, the pathological elevation of

MMP-9 levels is linked to white blood cell infiltration and blood-brain barrier damage (Cuello et al., 2012).Advanced investigations have shown that elevation of MMP-9 activity in the brain is an early occurrence since MMP-9 levels in the CSF of old individuals have previously expanded emphatically. MMP-9 levels in the CSF of old individuals might comprise a potential biomarker for the early finding of Alzheimer's infection (Ferretti and Cuello, 2011).

7.2. Blood-based Biomarkers

Aβ protein, Aβ autoantibodies, and platelet biomarkers are among the plasma and serum biomarkers that represent the underlying pathophysiological mechanism of senile plaque development.Isoforms of the platelet amyloid-β protein precursor (AβPP). Compared PET is expensive and scarce, owing to its high cost and scarcity. CSF imaging, as well as the invasive and specialized nature of the procedure because these blood samples are easier to acquire, are more accessible to researchers.the broader community.plasma and serum (Koyama et al., 2012).Studies on Aβ in plasma, on the other hand, are conflicting and indicate very minor variations between patients and controls. Although there is some evidence that alterations in plasma Aβ40 and Aβ42 are linked to those who are at risk for Alzheimer's disease, more research is needed (Rigman et al., 2008).Current cross-sectional and longitudinal cohort studies do not support the use of plasma A as a diagnostic marker for early Alzheimer's disease, implying that there is inadequate evidence of plasma Aβ40, Aβ42, or the ratio of Aβ42/Aβ40 functioning as biomarkers for preclinical Alzheimer's disease (Oskar, Hansson, et.al.2010).Cohort studies have produced similarly contradictory results, with greater Aβ42 baseline levels (Siderowf et al., 2010).Other investigations have found decreased plasma Aβ42 levels in patients with poor cognition (Lui et al., 2010).The Alzheimer's Diseases Neuroimaging Initiative (ADNI) found that plasma levels of Aβ40 and Aβ42 were only marginally useful as predictive indicators (Siderowf et al., 2010).Recent research suggests that, while individual measurements have limited predictive significance in any particular participant, plasma A's symptomatic commitment might be valuable when matched with a board of fringe markers (Rembach et al., 2014).This data suggests that additional improvements to plasma Aβ assays might help identify at-risk individuals in large-scale screening. A panel of blood-based biomarkers may reliably predict neocortical Aβ (extracellular Aβ) burden, according to a univariate analysis of ADNI research, confirming the concept of a link between a blood-based signature and Aβ accumulation (Burham et al., 2014). Besides, new proof that human serum incorporates steadily communicated

microRNAs (miRNAs) has uncovered a critical potential for serum miRNA profiles to be utilized as a unique finger impression for the analysis of Alzheimer's sickness (AD) (Tan et al., 2013; Tan et.al.,2014).Increasing evidence suggests that a serum miRNA panel (or only miR-342-3p) might serve as a potential biomarker for preclinical Alzheimer's disease diagnosis (Tan et al., 2014).As a result, while there is no practical blood biomarker for predicting AD conversion, combinations of plasma biomarkers might be utilized as surrogate indicators of disease risk for AD, particularly concerning awareness and explicitness, because of present deficient proof (Wang et al., 2014).

8.Symptoms of AD

8.1 Aphasia

Aphasia is the loss of spoken language, speech comprehension, reading, and writing skills as a result of brain damage caused by neuropathology, such as Alzheimer's disease (AD).The degradation of brain tissue causes ADOD, which is accompanied by behavioral and functional loss, including communication difficulties.A mind with neuropathology is bound to be harmed.Neurodegeneration will strike a network or area, and because a vast spectrum of brain processes are required for normal language function ADOD will almost certainly result inthe aphasia of some sort or another. It's not the neuropathology of Alzheimer's infection generally, yet the mind association. Affected is a term that portrays the signs and results of aphasia, such as Pathology in the medial temporal lobes and associative memory are likely to be affected by Alzheimer's disease regions first so the side effects of Alzheimer's infection can be recognized before the beginning of rambling memory weaknesses (Weekes, 2020).

8.2 Amnesia

Memory loss is referred to as amnesia, and it is most obvious in patients with Alzheimer's disease when they first have trouble with short-term memory,which then forms into a decrease in long haul memory. Communication problems arise as memory loss advances. Because affected persons cannot remember large amounts of information, such as several directions, caregivers should communicate in short, straightforward words at a considerably slower speed.

8.3 Apraxia

Apraxia is a condition where purposeful motor limits are lost. The troubled individual loses the ability to perform principal developments and activities. Because the brain and the muscles necessary to complete a job are unable to communicate, people lose the capacity to

do daily tasks such as washing, dressing, walking, and eating. There is a substantial danger of falling as a result of these modifications. Keeping the individual with apraxia as active as possible may assist to postpone the physical changes.

8.4 Agnosia

The inability to identify things, people, sounds, or locations is known as agnosia. The affected individual loses not just the capacity to identify the thing (they may make up a word), but also the ability to describe how it is used. Guardians ought to make signals, for example, highlighting things that the individual might require, like a brush, brush, fork, or spoon.

8.5 Anomia

Anomia is a condition in which the brain's signaling fails and the person has trouble finding the proper word. An individual understands what they need and what it does, but they can't find the right term to describe it. Again, gestures and inquiries with two or three options, such as "Would you want cereal or eggs for breakfast?" may be helpful.

9.Prevention

There is reason to be optimistic about multimodal therapies that include exercise, lifestyle improvements, and cognitive stimulation for the prevention of cognitive deterioration related to Alzheimer's disease. (Fink et al., 2018).There is motivation to be hopeful about multimodal treatments that incorporate activity, lifestyle improvements, and cognitive stimulation for the prevention of cognitive deterioration related to Alzheimer's disease (Ngandu et al., 2015).When paired with concentrated attention on other changeable habits or situations,the beginning of obvious mental deterioration may be postponed. If implemented by midlife, lifestyle and medical measures may help to lessen the burden of cerebrovascular illness. Preventive measures that are implemented by midlife or earlier may help to minimize the burden of cerebrovascular illness Preventive measures that are implemented by midlife or earlier may help to minimize the burden of cerebrovascular illness Preventive measures that are implemented by midlife or earlier may help to minimize the burden of cerebrovascular illness If implemented by midlife, procedures might assist with reducing the weight of cerebrovascular illness (Debette et al., 2011).Albeit the security of focusing on a systolic circulatory strain of 120 mmHg in more established individuals is discussed, a preliminary of forceful pulse decrease in individuals who were believed to be intellectually healthy at enrolment across the age scope of 50 years and more established (counting 28% who were

beyond 75 a years old) brought about a lower pace of episode MCI and dementia (Williamson et al., 2019).The decreased absolute weight of cerebrum ailment of any etiology in intellectually articulate mind regions would expand how much AD-related pathology is expected to incite side effects, hence delaying symptomatic disease due to AD through an indirect mechanism.

10.Management

While patients are as yet residing locally, the greater part of treatment and the executives for patients with MCI and dementia inferable from AD (as well as most all-cause MCI and dementia) happens in the short term climate.From the time expert points of interaction with patients and their families, the leaders start. Family minds bear a critical piece of the illness' weight. Establishing rapport, trust, and realistic expectations requires compassion, tolerance, and a lack of condescension. Explicit training in this new job may be beneficial to many. The Alzheimer's Association in the United States and its sister organization's in other countries have made it a priority to support caregivers.The Alzheimer's Association in the United States and its international affiliateshave made caregiver assistance a top goal (Reuben et al., 2020).The family's acceptance of the diagnosis is a necessary step before more advanced therapy approaches may be implemented. Many people with MCI or dementia as a result of Alzheimer's disease (AD) show a severe loss of awareness of their deficiencies and limits. The family caregiver, who is frequently a spouse, adult child, or sibling, may bear the brunt of the diagnostic disclosure. Because the complexity and emotional preparation of each patient and their family caregivers varies, the diagnosis must be adjusted to the scenario (John et al., 2007).The incorporation of biomarkers into the diagnostic procedure has made delivering an MCI or dementia diagnosis more difficult (Alpinar-Sencan and Schicktanz et al., 2020).when the differences between symptoms and etiologies grow increasingly complicated and confusing to laypeople.

Patients with gentle to extreme dementia brought about by Alzheimer's infection ought to be encouraged to be as socially, intellectually, and actually dynamic as could really be expected.Since sustenance has not been found to change the development of intriguing mental impedance in Alzheimer's contamination, eating a 'heart-sound' diet can be supported without specific food proposals.Individualized treatments, instead of methodical gathering intercessions like mental excitement, ought to be leaned toward since they might defer systematization (Amieva et al., 2016).

11.Treatment of Alzheimer's disease

In the new ten years, a significant part of the exploration of Alzheimer's sickness has centered around infection adjusting treatments that influence the course of the disease instead of treating side effects alone.However, the paucity of effective disease-modifying medications discovered in this research underlines the difficulties in discovering a therapeutic agent capable of altering the course of a disease as complicated as Alzheimer's (Salvatore et al., 2012).

11.1 Cholinesterase Inhibitors

The decrease in acetylcholine (ACh) creation causes Alzheimer's disease. One of the treatment choices for further developing mental and brain cell execution is to upgrade cholinergic levels by hindering acetylcholinesterase (AChE).AChEIs stop acetylcholine from being degraded in synapses,achieving an improvement of ACh and fervor of cholinergic receptors. Tacrine (tetrahydroaminoacridine) is a cholinesterase inhibitor drug upheld for the treatment of Alzheimer's illness that works by expanding ACh in muscarinic neurons. Anyway, it was quickly taken off the market due to a high rate of side effects such as hepatotoxicity,what's more, an absence of advantages that were seen in a few preliminaries (Anand and Baldev, 2013).Increased choline reuptake and, thus, expanded acetylcholine creation at the presynaptic terminals is another procedure that might help with the treatment of AD.This can be accomplished by focusing on the choline transporter (CHT1), which is answerable for giving choline to ACh creation.Drugs that increase CHT1 at the plasma membrane may be the future treatment for Alzheimer's disease (Ferreira-Vieira et al., 2016).

11.2 Donepezil

Donepezil is an indanone-benzyl piperidine subordinate that has a place in the second era of AChEIs and is generally used to treat Alzheimer's sickness. Donepezil hinders acetylcholine hydrolysis by reversibly restricting to acetylcholinesterase, bringing about a more prominent grouping of ACh at neurotransmitters. The medicine is all around endured, with exceptionally minor and brief cholinergic aftereffects influencing the gastrointestinal and neurological frameworks. Donepezil is a drug that is used to treat symptoms of Alzheimer's disease, such as enhancing cognition and behavior without slowing down the disease's progression (Mukata and Harriet, 2000).

11.3 Rivastigmine

Rivastigmine is a pseudo irreversible inhibitor of AChE and butyrylcholinesterase (BuChE) that works by blocking ACh handling by restricting the two strong locales of AChE (anionic and dull complaints). BuChE is overall certain in glial cells. Rivastigmine separates more leisurely than AChE, which is the reason it's alluded to as a pseudo-irreversible, and it's separated by AChE and BuChE at the neural connection. It upgrades mental capacities and ordinary undertakings. The medication's oral organization is connected to secondary effects like queasiness, retching, dyspepsia, asthenia, anorexia, and weight reduction. By and large, these antagonistic impacts are the essential driver for suspending treatment; by the by, they can be overseen over the long haul (Khoury et al., 2018).

11.4 Galantamine

Galantamine is a first-line therapy for fragile to facilitate Alzheimer's infection. Lady is a particular tertiary isoquinoline alkaloid with a double method of activity, going about asaferocious inhibitor of AChE and beginning nicotinic acetylcholine receptors by restricting allosterically to the - subunit. Lady, like other AChE inhibitors, can enhance behavioral symptoms, everyday activities, and cognitive performance with high effectiveness and tolerance (Wahba et al., 2016).

11.5 N-methyl D-aspartate(NMDA) Antagonists

NMDAR is remembered to play a vital part in the pathogenesis of Alzheimer's sickness.NMDAR activation causes Ca2+ influx, which increases signal transduction and, accordingly, quality record, which is expected for the formation of long haul potentiation (LTP), which is imperative for synaptic neurotransmission, malleability, and memory arrangement.Overactivation of NMDARs results in aberrant Ca2+ signaling and glutamate overstimulation, the major excitatory amino acid in the CNS, resulting in excitotoxicity, synaptic dysfunction, neuronal cell death, and a loss of cognitive skills (Huang, Yu-Jhen, et al., 2012).

11.6 Memantine

Memantine is a low-liking noncompetitive bad guy of the NMDAR, a glutamate receptor subtype that hinders over-initiation of the glutaminergic framework, which is implicated in neurotoxicity in Alzheimer's disease.Memantine is utilized to get moderate extreme Alzheimer's sickness,either alone or connected with AChEI. The medication is protected and very much endured since it blocks excitatory receptors without disrupting ordinary synaptic

transmission. This is owing to memantine's low affinity, as it is quickly displaced from NMDAR by high glutamate concentrations, preventing a protracted blockage (Folch et al., 2017).

12. CONCLUSION

The arising subtleties of AD pathophysiology give conceivable remedial focuses to the treatment of AD. β-amyloid plaques and NFTs are for quite some time held signs of AD. The infection is currently viewed as a continuum, where the main stage starts a very long time before the clinical side effects emerge.Promotion begins progressively, it at first incorporates the piece of the frontal cortex that controls thought, memory, and language. individuals with AD could experience inconvenience surveying the things or names of individuals.The side effects deteriorate after some time. They may have trouble speaking, reading, or writing.AD patients can cause great stress to their family members. AD usually begins after the age of 60 years. The risk goes up as you progress in years. Maturing, natural components, and metals are a portion of the gamble factors for AD. Presently, there is no solution for AD, yet accessible drugs briefly sluggish the deteriorating of AD side effects and help with conduct issues that might show up during the sickness.The food and medication administration(FDA) at this point maintained two classes of medications these are cholinesterase inhibitors and NMDA miscreants. Cholinesterase inhibitors are utilized to treat fragile to facilitate AD accidental impacts. These medications incorporate Donepezil, rivastigmine, and galantamine.These work by thwarting the activity of acetylcholinesterase, the compound in danger of destroying acetylcholine. NMDA miscreant drug is memantine used for the treatment of moderate to genuine AD.It impedes the synapse glutamate from actuating NMDA receptors on nerve cells and keeps the nerve cell better. Memantine can be taken alone or alongside a cholinesterase inhibitor.

REFERENCES

1. A. Armstrong, Richard (2013). Review article What causes alzheimer’s disease?. Folia Neuropathologica, 3(3): 169–188. doi:10.5114/fn.2013.37702.
2. Adlard, Paul A.; Bush, Ashley I.; Perry, George; Avila, Jesus; Zhu, Xiongwei (2018). Metals and Alzheimer’s Disease: How Far Have We Come in the Clinic?. Journal of Alzheimer's Disease, 62(3): 1369–1379. doi:10.3233/JAD-170662.
3. Akira Yamamoto; Ryong-Woon Shin; Kazuhiro Hasegawa; Hironobu Naiki; Hiroyuki Sato; Fumio Yoshimasu; Tetsuyuki Kitamoto (2002). Iron (III) induces aggregation of

hyperphosphorylated τ and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease., 82(5): 1137–1147. doi:10.1046/j.1471-4159.2002.t01-1-01061.x.

4. Alain R. Simard; Denis Soulet; Genevieve Gowing; Jean-Pierre Julien; Serge Rivest (2006). Bone Marrow-Derived Microglia Play a Critical Role in Restricting Senile Plaque Formation in Alzheimer's Disease., 49(4): 0–502. doi:10.1016/j.neuron.2006.01.022.
5. Alfred Maelicke; Marek Samochocki; Ruth Jostock; Andreas Fehrenbacher; Jürgen Ludwig; Edson X Albuquerque; Marion Zerlin (2001). Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease., 49(3): 279–288. doi:10.1016/s0006-3223(00)01109-4.
6. Alix de Calignon; Manuela Polydoro; Marc Suárez-Calvet; Christopher William; David H. Adamowicz; Kathy J. Kopeikina; Rose Pitstick; Naruhiko Sahara; Karen H. Ashe; George A. Carlson; Tara L. Spires-Jones; Bradley T. Hyman (2012). Propagation of Tau Pathology in a Model of Early Alzheimer's Disease., 73(4): 0–697. doi:10.1016/j.neuron.2011.11.033.
7. Alpinar-Sencan Z & Schicktanz S Addressing ethical challenges of disclosure in dementia prediction: limitations of current guidelines and suggestions to proceed. BMC Med. Ethics, 2020; 21, 33.
8. Alzheimer's Association. Early-onset dementia: a national challenge, a future crisis. Published, 2006 Accessed November 27, 2018.
9. Amieva, Hélène; Robert, Philippe H.; Grandoulier, Anne-Sophie; Meillon, Céline; De Rotrou, Jocelyne; Andrieu, Sandrine; Berr, Claudine; Desgranges, Béatrice; Dubois, Bruno; Girtanner, Chantal; Joël, Marie-Eve; Lavallart, Benoit; Nourhashemi, Fati; Pasquier, Florence; Rainfray, Muriel; Touchon, Jacques; Chêne, Geneviève; Dartigues, Jean-François (2016). Group and individual cognitive therapies in Alzheimer's disease: the ETNA3 randomized trial. International Psychogeriatrics, 28(5): 707–717. doi:10.1017/s1041610215001830.
10. Anand, Preet; Singh, Baldev (2013). A review on cholinesterase inhibitors for Alzheimer's disease. Archives of Pharmacal Research, 36(4): 375–399. doi:10.1007/s12272-013-0036-3
11. André Delacourte; Nicolas Sergeant; Annick Wattez; Claude-Alain Maurage; Florence Lebert; Florence Pasquier; Jean-Philippe David (2002). Tau aggregation in the hippocampal formation: an ageing or a pathological process?., 37(10-11): 1291–1296. doi:10.1016/s0531-5565(02)00141-9.

12. Anne M. Fagan; Mark A. Mintun; Aarti R. Shah; Patricia Aldea; Catherine M. Roe; Robert H. Mach; Daniel Marcus; John C. Morris; David M. Holtzman (2009). Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease., 1(8-9): 371–380. doi:10.1002/emmm.200900048.
13. Antonella Caccamo; Salvatore Oddo; Lauren M. Billings; Kim N. Green; Hilda Martinez-Coria; Abraham Fisher; Frank M. LaFerla (2006). M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice., 49(5): 0–682. doi:10.1016/j.neuron.2006.01.020.
14. Arispe, N.; Pollard, H. B.; Rojas, E. (1996). Zn2+ interaction with Alzheimer amyloid beta protein calcium channels.. Proceedings of the National Academy of Sciences, 93(4): 1710–1715. doi:10.1073/pnas.93.4.1710.
15. Arnold, S. E.; Hyman, B. T.; Flory, J.; Damasio, A. R.; Van Hoesen, G. W. (1991). The Topographical and Neuroanatomical Distribution of Neurofibrillary Tangles and Neuritic Plaques in the Cerebral Cortex of Patients with Alzheimer's Disease. Cerebral Cortex, 1(1): 103–116. doi:10.1093/cercor/1.1.103.
16. Ashok, A.; Rai, N. K.; Tripathi, S.; Bandyopadhyay, S. (2015). Exposure to As-, Cd-, and Pb-Mixture Induces A, Amyloidogenic APP Processing and Cognitive Impairments via Oxidative Stress-Dependent Neuroinflammation in Young Rats. Toxicological Sciences, 143(1): 64–80. doi:10.1093/toxsci/kfu208.
17. B Connor; D Young; Q Yan; R.L.M Faull; B Synek; M Dragunow (1997). Brain-derived neurotrophic factor is reduced in Alzheimer's disease., 49(1-2): 0–81. doi:10.1016/s0169-328x(97)00125-3.
18. Bartolotti, N; Bennett, D A; Lazarov, O (2016). Reduced pCREB in Alzheimer’s disease prefrontal cortex is reflected in peripheral blood mononuclear cells. Molecular Psychiatry, 21(9): 1158–1166. doi:10.1038/mp.2016.111.
19. Benarroch, Eduardo E. (2018). Glutamatergic synaptic plasticity and dysfunction in Alzheimer disease. Neurology, 10.1212/WNL.0000000000005807–. doi:10.1212/WNL.0000000000005807.
20. Berr, Claudine; Hauw, Jean-Jacques; Delaère, Pia; Duyckaerts, Charles; Amouyel, Philippe (1994). Apolipoprotein E allele ε4 is linked to increased deposition of the amyloid β-peptide (A-β) in cases with or without Alzheimer's disease., 178(2): 221–224. doi:10.1016/0304-3940(94)90763-3.

21. Birge, S. J. (1997). The role of estrogen in the treatment of Alzheimer's disease. Neurology, 48(Issue 5, Supplement 7): 36S–41S. doi:10.1212/WNL.48.5_Suppl_7.36S.
22. Blaine R. Roberts; Timothy M. Ryan; Ashley I. Bush; Colin L. Masters; James A. Duce (2012). The role of metallobiology and amyloid-β peptides in Alzheimer's disease., 120(Supplement s1): 149–166. doi:10.1111/j.1471-4159.2011.07500.x.
23. Bodick, N. C.; Offen, W. W.; Levey, A. I.; Cutler, N. R.; Gauthier, S. G.; Satlin, A.; Shannon, H. E.; Tollefson, G. D.; Rasmussen, K.; Bymaster, F. P.; Hurley, D. J.; Potter, W. Z.; Paul, S. M. (1997). Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease. Archives of Neurology, 54(4): 465–473. doi:10.1001/archneur.1997.00550160091022.
24. Boespflug, Erin L.; Iliff, Jeffrey J. (2017). The emerging relationship between interstitial fluid-cerebrospinal fluid exchange, amyloid β and sleep. Biological Psychiatry, S0006322317322540–. doi:10.1016/j.biopsych.2017.11.031.
25. Boyle, Patricia A.; Yu, Lei; Wilson, Robert S.; Leurgans, Sue E.; Schneider, Julie A.; Bennett, David A. (2017). Person-specific contribution of neuropathologies to cognitive loss in old age. Annals of Neurology, doi:10.1002/ana.25123.
26. Braak, Heiko; Thal, Dietmar R.; Ghebremedhin, Estifanos; Del Tredici, Kelly (2011). Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years. Journal of Neuropathology & Experimental Neurology, 70(11): 960–969. doi:10.1097/NEN.0b013e318232a379.
27. Brenner, Daniel E.; Kukull, Walter A.; Stergachis, Andy; van Belle, Gerald; Bowen, James D.; McCormick, Wayne C.; Ten, Linda; Larson, Eric B. (1994). Postmenopausal Estrogen Replacement Therapy and the Risk of Alzheimer's Disease: A Population-based Case-Control Study. American Journal of Epidemiology, 140(3): 262–267. doi:10.1093/oxfordjournals.aje.a117245.
28. Buchhave, Peder (2012). Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia. Archives of General Psychiatry, 69(1): 98–. doi:10.1001/archgenpsychiatry.2011.155.
29. Burnham, S C; Faux, N G; Wilson, W; Laws, S M; Ames, D; Bedo, J; Bush, A I; Doecke, J D; Ellis, K A; Head, R; Jones, G; Kiiveri, H; Martins, R N; Rembach, A; Rowe, C C; Salvado, O; Macaulay, S L; Masters, C L; Villemagne, V L (2014). A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study. Molecular Psychiatry, 19(4): 519–526. doi:10.1038/mp.2013.40.

30. Busche, Marc Aurel; Hyman, Bradley T. (2020). Synergy between amyloid-Î² and tau in Alzheimerâ ™s disease. Nature Neuroscience, doi:10.1038/s41593-020-0687-6.
A. HOCK; A. MADDALENA; I. HEUSER; D. NABER; W. OERTEL; H. VON DER KAMMER; M. WIENRICH; A. RASCHIG; M. DENG; J. H. GROWDON; R. M. NITSCH (2000). Treatment with the Selective Muscarinic Agonist Talsaclidine Decreases Cerebrospinal Fluid Levels of Total Amyloid β-Peptide in Patients with Alzheimer's Disease., 920(none): 285–291. doi:10.1111/j.1749-6632.2000.tb06937.x.
31. C.A. Davies; D.M.A. Mann; P.Q. Sumpter; P.O. Yates (1987). A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease., 78(2): 151–164. doi:10.1016/0022-510x(87)90057-8.
32. Caspersen, C. (2005). Mitochondrial A : a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. The FASEB Journal, (0): 347–356. doi:10.1096/fj.05-3735fje.
33. Cathy Andorfer; Yvonne Kress; Marisol Espinoza; Rohan De Silva; Kerry L. Tucker; Yves-Alain Barde; Karen Duff; Peter Davies (2003). Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms., 86(3): 582–590. doi:10.1046/j.1471-4159.2003.01879.x.
34. Chang, Ki Jung; Hong, Chang Hyung; Lee, Kang Soo; Kang, Dae Ryong; Lee, Jeong Dong; Choi, Seong Hye; Kim, Seong Yoon; Na, Duk L.; Seo, Sang Won; Kim, Do-Kwan; Lee, Yunhwan; Chung, Young Ki; Lim, Ki Young; Noh, Jai Sung; Park, Jungsik; Son, Sang Joon (2017). Mortality Risk after Diagnosis of Early-Onset Alzheimer's Disease versus Late-Onset Alzheimer's Disease: A Propensity Score Matching Analysis. Journal of Alzheimer's Disease, 56(4): 1341–1348. doi:10.3233/JAD-161181.
35. Chapuis J, Flaig A, Grenier-Boley B, Eysert F, Pottiez V, Deloison G, Vandeputte A, Ayral AM, Medes T, Desai S, Goate AM, Kauwe JSK, Leroux F, Herledan A, Demiautte F, Bauer C, Checler F,Petersen RC, Blennow K, Zetterberg H, Minthon L, Van Deerlin VM, Lee VMY, Shaw LM, Trojanowski JQ, Albert M, Moghekar A, O'Brien R, Peskind ER, Malmanche N, Schellenberg GD,Dourien P, Song OR, Cruchaga C, Amouyel P, deprez B, Brodin P,Lambert JC. Genome-wide, high content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism. Acta Neuropathol, 2017; 133: 955-966.
36. Chartier-Harlin, Marie-Christine; Crawford, Fiona; Houlden, Henry; Warren, Andrew; Hughes, David; Fidani, Liana; Goate, Alison; Rossor, Martin; Roques, Penelope; Hardy,

John (1991). Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene., 353(6347): 844–846. doi:10.1038/353844a0.

37. Cho, D.-H.; Nakamura, T.; Fang, J.; Cieplak, P.; Godzik, A.; Gu, Z.; Lipton, S. A. (2009). S-Nitrosylation of Drp1 Mediates -Amyloid-Related Mitochondrial Fission and Neuronal Injury. Science, 324(5923): 102–105. doi:10.1126/science.1171091.
38. Christian Humpel (2011). Identifying and validating biomarkers for Alzheimer's disease., 29(1): 26–32. doi:10.1016/j.tibtech.2010.09.007.
39. Colditz, Graham A.; Hankinson, Susan E.; Hunter, David J.; Willett, Walter C.; Manson, JoAnn E.; Stampfer, Meir J.; Hennekens, Charles; Rosner, Bernard; Speizer, Frank E. (1995). The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women., 332(24): 1589–1593. doi:10.1056/nejm199506153322401.
40. Combs, Colin K.; Karlo, J. Colleen; Kao, Shih-Chu; Landreth, Gary E. (2001). β-Amyloid Stimulation of Microglia and Monocytes Results in TNFα-Dependent Expression of Inducible Nitric Oxide Synthase and Neuronal Apoptosis. The Journal of Neuroscience, 21(4): 1179–1188. doi:10.1523/JNEUROSCI.21-04-01179.2001.
41. Cooper, J. D.; Salehi, A.; Delcroix, J.-D.; Howe, C. L.; Belichenko, P. V.; Chua-Couzens, J.; Kilbridge, J. F.; Carlson, E. J.; Epstein, C. J.; Mobley, W. C. (2001). Failed retrograde transport of NGF in a mouse model of Down's syndrome: Reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proceedings of the National Academy of Sciences, 98(18): 10439–10444. doi:10.1073/pnas.181219298.
42. Craft, S.; Peskind, E.; Schwartz, M. W.; Schellenberg, G. D.; Raskind, M.; Porte, D. (1998). Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: Relationship to severity of dementia and apolipoprotein E genotype. Neurology, 50(1): 164–168. doi:10.1212/WNL.50.1.164.
43. Crary, John F.; Trojanowski, John Q.; Schneider, Julie A.; Abisambra, Jose F.; Abner, Erin L.; Alafuzoff, Irina; Arnold, Steven E.; Attems, Johannes; Beach, Thomas G.; Bigio, Eileen H.; Cairns, Nigel J.; Dickson, Dennis W.; Gearing, Marla; Grinberg, Lea T.; Hof, Patrick R.; Hyman, Bradley T.; Jellinger, Kurt; Jicha, Gregory A.; Kovacs, Gabor G.; Knopman, David S.; Kofler, Julia; Kukull, Walter A.; Mackenzie, Ian R.; Masliah, Eliezer; McKee, Ann; Montine, Thomas J.; Murray, Melissa E.; Neltner, Janna H.; Santa-Maria, Ismael; Seeley, William W.; Serrano-Pozo, Alberto; Shelanski, Michael L.; Stein, Thor; Takao, Masaki; Thal, Dietmar R.; Toledo, Jonathan B.; Troncoso, Juan C.; Vonsattel, Jean Paul; White, Charles L.; Wisniewski, Thomas; Woltjer, Randall L.; Yamada, Masahito; Nelson, Peter T. (2014). Primary age-related tauopathy (PART): a

common pathology associated with human aging. Acta Neuropathologica, 128(6): 755–766. doi:10.1007/s00401-014-1349-0.

44. Cuello, A.C.; Ferretti, M.T.; Iulita, M.F. (2012). Preplaque (‘Preclinical’) Aß-Induced Inflammation and Nerve Growth Factor Deregulation in Transgenic Models of Alzheimer’s Disease-Like Amyloid Pathology. Neurodegenerative Diseases, 10(1-4): 104–107. doi:10.1159/000333339.
45. D.L. Miller; I.A. Papayannopoulos; J. Styles; S.A. Bobin; Y.Y. Lin; K. Biemann; K. Iqbal (1993). Peptide Compositions of the Cerebrovascular and Senile Plaque Core Amyloid Deposits of Alzheimer′s Disease., 301(1): 0–52. doi:10.1006/abbi.1993.1112.
46. Debette, S.; Seshadri, S.; Beiser, A.; Au, R.; Himali, J. J.; Palumbo, C.; Wolf, P. A.; DeCarli, C. (2011). Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology, 77(5): 461–468. doi:10.1212/wnl.0b013e318227b227.
47. Degenhardt, Elisabeth K.; Witte, Michael M.; Case, Michael G.; Yu, Peng; Henley, David B.; Hochstetler, Helen M.; D’Souza, Deborah N.; Trzepacz, Paula T. (2016). Florbetapir F18 PET Amyloid Neuroimaging and Characteristics in Patients With Mild and Moderate Alzheimer Dementia. Psychosomatics, 57(2): 208–216. doi:10.1016/j.psym.2015.12.002.
48. Delacourte, A.; Sergeant, N.; Champain, D.; Wattez, A.; Maurage, C.-A.; Lebert, F.; Pasquier, F.; David, J.-P. (2002). Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology, 59(3): 398–407. doi:10.1212/wnl.59.3.398.
49. Domenico Praticò (2008). Oxidative stress hypothesis in Alzheimer’s disease: a reappraisal., 29(12): 0–615. doi:10.1016/j.tips.2008.09.001.
50. Dominic M. Walsh; Dennis J. Selkoe (2007). Aβ Oligomers – a decade of discovery., 101(5): 1172–1184. doi:10.1111/j.1471-4159.2006.04426.x.
51. Donata Paternicò; Samantha Galluzzi; Valeria Drago; Luisella Bocchio-Chiavetto; Roberta Zanardini; Laura Pedrini; Manuela Baronio; Giovanni Amicucci; Giovanni B. Frisoni (2012). Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults., 8(6): doi:10.1016/j.jalz.2011.10.003.
52. Du, Ke; Liu, Mingyan; Pan, Yanzhu; Zhong, Xin; Wei, Minjie (2017). Association of Serum Manganese Levels with Alzheimer’s Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis. Nutrients, 9(3): 231–. doi:10.3390/nu9030231.
53. Dugger, Brittany N.; Hentz, Joseph G.; Adler, Charles H.; Sabbagh, Marwan N.; Shill, Holly A.; Jacobson, Sandra; Caviness, John N.; Belden, Christine; Driver-Dunckley, Erika; Davis, Kathryn J.; Sue, Lucia I.; Beach, Thomas G. (2014). Clinicopathological

Outcomes of Prospectively Followed Normal Elderly Brain Bank Volunteers. Journal of Neuropathology & Experimental Neurology, 73(3): 244–252. doi:10.1097/NEN.0000000000000046.

54. Dujardin, Simon; Commins, Caitlin; Lathuiliere, Aurelien; Beerepoot, Pieter; Fernandes, Analiese R.; Kamath, Tarun V.; De Los Santos, Mark B.; Klickstein, Naomi; Corjuc, Diana L.; Corjuc, Bianca T.; Dooley, Patrick M.; Viode, Arthur; Oakley, Derek H.; Moore, Benjamin D.; Mullin, Kristina; Jean-Gilles, Dinorah; Clark, Ryan; Atchison, Kevin; Moore, Renee; Chibnik, Lori B.; Tanzi, Rudolph E.; Frosch, Matthew P.; Serrano-Pozo, Alberto; Elwood, Fiona; Steen, Judith A.; Kennedy, Matthew E.; Hyman, Bradley T. (2020). Tau molecular diversity contributes to clinical heterogeneity in Alzheimerâ ™s disease. Nature Medicine, doi:10.1038/s41591-020-0938-9.
55. Edith G. McGeer; Koji Yasojima; Claudia Schwab; Patrick L. McGeer (2001). The pentraxins: possible role in Alzheimer's disease and other innate inflammatory diseases., 22(6): 0–848. doi:10.1016/s0197-4580(01)00288-3.
56. Edward Renvoize; Mandy Hanson; Mark Dale (2011). Prevalence and causes of young onset dementia in an English health district., 26(1): 106–107. doi:10.1002/gps.2456.
57. Eftekharzadeh, Bahareh; Daigle, J. Gavin; Kapinos, Larisa E.; Coyne, Alyssa; Schiantarelli, Julia; Carlomagno, Yari; Cook, Casey; Miller, Sean J.; Dujardin, Simon; Amaral, Ana S.; Grima, Jonathan C.; Bennett, Rachel E.; Tepper, Katharina; DeTure, Michael; Vanderburgh, Charles R.; Corjuc, Bianca T.; DeVos, Sarah L.; Gonzalez, Jose Antonio; Chew, Jeannie; Vidensky, Svetlana; Gage, Fred H.; Mertens, Jerome; Troncoso, Juan; Mandelkow, Eckhard; Salvatella, Xavier; Lim, Roderick Y.H.; Petrucelli, Leonard; Wegmann, Susanne; Rothstein, Jeffrey D.; Hyman, Bradley T. (2018). Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer's Disease. Neuron, 99(5): 925–940.e7. doi:10.1016/j.neuron.2018.07.039.
58. Eriksson H, Fereshtehnejad SM, Falahati F, et al. Differences in routine clinical practice between early and late onset Alzheimer's disease: data from the Swedish Dementia Registry (SveDem). J Alzheimers Dis, 2014; 41(2): 411–419. doi:10.3233/JAD-132273.
59. Fagan, Anne M. (2011). Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of β-Amyloid 1-42, Total tau, and P-tau₁₈₁ for Identifying Alzheimer Disease Amyloid Plaque Pathology. Archives of Neurology, 68(9): 1137–. doi:10.1001/archneurol.2011.105.
60. Farris, W.; Mansourian, S.; Chang, Y.; Lindsley, L.; Eckman, E. A.; Frosch, M. P.; Eckman, C. B.; Tanzi, R. E.; Selkoe, D. J.; Guenette, S. (2003). Insulin-degrading

enzyme regulates the levels of insulin, amyloid -protein, and the -amyloid precursor protein intracellular domain in vivo. Proceedings of the National Academy of Sciences, 100(7): 4162–4167. doi:10.1073/pnas.0230450100.

61. Fiala, Milan; Lin, Justin; Ringman, John; Kermani-Arab, Vali; Tsao, George; Patel, Amish; Lossinsky, Albert S.; Graves, Michael C.; Gustavson, Andrew; Sayre, James; Sofroni, Emanuela; Suarez, Tatiana; Chiappelli, Francesco; Bernard, George (2005). Ineffective phagocytosis of amyloid-β by macrophages of Alzheimer's disease patients. Journal of Alzheimer's Disease, 7(3): 221–232. doi:10.3233/JAD-2005-7304.
62. Fink, Howard A.; Jutkowitz, Eric; McCarten, J. Riley; Hemmy, Laura S.; Butler, Mary; Davila, Heather; Ratner, Edward; Calvert, Collin; Barclay, Terry R.; Brasure, Michelle; Nelson, Victoria A.; Kane, Robert L. (2018). Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia. Annals of Internal Medicine, 168(1): 39–. doi:10.7326/M17-1529.
63. Flavio Kamenetz; Taisuke Tomita; Helen Hsieh; Guy Seabrook; David Borchelt; Takeshi Iwatsubo; Sangram Sisodia; Roberto Malinow (2003). APP Processing and Synaptic Function., 37(6): 0–937. doi:10.1016/s0896-6273(03)00124-7.
64. Folch, Jaume; Busquets, Oriol; Ettcheto, Miren; Sánchez-López, Elena; Castro-Torres, Ruben Dario; Verdaguer, Ester; Garcia, Maria Luisa; Olloquequi, Jordi; Casadesús, Gemma; Beas-Zarate, Carlos; Pelegri, Carme; Vilaplana, Jordi; Auladell, Carme; Camins, Antoni (2017). Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. Journal of Alzheimer's Disease, 1–18. doi:10.3233/JAD-170672.
65. Fryer JD, Taylor JW, DeMattos RB, Bates KR, Paul SM, Parsadamian M, Holtzman DM. Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice.J Neurosci, 2003; 23: 7889-7896. doi:10.3233/JAD-2011-101401.
66. Fumitaka Oyama; Hiroyuki Shimada; Rieko Oyama; Yasuo Ihara (1995). Apolipoprotein E genotype, Alzheimer's pathologies and related gene expression in the aged population., 29(1): 92–98. doi:10.1016/0169-328x(94)00233-5.
67. Gabriele Cipriani; Cristina Dolciotti; Lucia Picchi; Ubaldo Bonuccelli (2011). Alzheimer and his disease: a brief history., 32(2): 275–279. doi:10.1007/s10072-010-0454-7.
68. Gael Barthet; Julie Dunys; Zhiping Shao; Zhao Xuan; Yimin Ren; Jindong Xu; Nicolas Arbez; Gweltas Mauger; Julien Bruban; Anastasios Georgakopoulos; Junichi Shioi; Nikolaos K. Robakis (2013). Presenilin mediates neuroprotective functions of ephrinB and brain-derived neurotrophic factor and regulates ligand-induced internalization and

metabolism of EphB2 and TrkB receptors., 34(2): –. doi:10.1016/j.neurobiolaging.2012.02.024.

69. Garzon, D. J.; Fahnestock, M. (2007). Oligomeric Amyloid Decreases Basal Levels of Brain-Derived Neurotrophic factor (BDNF) mRNA via Specific Downregulation of BDNF Transcripts IV and V in Differentiated Human Neuroblastoma Cells. Journal of Neuroscience, 27(10): 2628–2635. doi:10.1523/JNEUROSCI.5053-06.2007.
70. Gerritsen, Adrie A.J.; Bakker, Christian; Verhey, Frans R.J.; de Vugt, Marjolein E.; Melis, René J.F.; Koopmans, Raymond T.C.M. (2016). Prevalence of Comorbidity in Patients With Young-Onset Alzheimer Disease Compared With Late-Onset: A Comparative Cohort Study. Journal of the American Medical Directors Association, 17(4): 318–323. doi:10.1016/j.jamda.2015.11.011.
71. Gessel, Megan Murray; Bernstein, Summer; Kemper, Martin; Teplow, David B.; Bowers, Michael T. (2012). Familial Alzheimer's Disease Mutations Differentially Alter Amyloid β-Protein Oligomerization. ACS Chemical Neuroscience, 3(11): 909–918. doi:10.1021/cn300050d.
72. Giancarlo Zatti; Andrea Burgo; Marta Giacomello; Laura Barbiero; Roberta Ghidoni; Giulietta Sinigaglia; Cristina Florean; Silvia Bagnoli; Giuliano Binetti; Sandro Sorbi; Paola Pizzo; Cristina Fasolato (2006). Presenilin mutations linked to familial Alzheimer's disease reduce endoplasmic reticulum and Golgi apparatus calcium levels., 39(6): 539–550. doi:10.1016/j.ceca.2006.03.002.
73. Gibb, W R; Lees, A J (1988). The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.., 51(6): 745–752. doi:10.1136/jnnp.51.6.745.
74. Gillis, Cai; Mirzaei, Fariba; Potashman, Michele; Ikram, M. Arfan; Maserejian, Nancy (2019). The incidence of mild cognitive impairment: A systematic review and data synthesis. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 11 : 248–256. doi:10.1016/j.dadm.2019.01.004.
75. Golde, Todd E.; DeKosky, Steven T.; Galasko, Douglas (2018). Alzheimer's disease: The right drug, the right time. Science, 362(6420): 1250–1251. doi:10.1126/science.aau0437
76. Graff-Radford, J., Yong, K. X. X., Apostolova, L. G., Bouwman, F. H., Carrillo, M., Dickerson, B. C., … Murray, M. E. (2021). New insights into atypical Alzheimer's disease in the era of biomarkers. The Lancet Neurology, 20(3): 222–234. doi:10.1016/s1474-4422(20)30440-3.
77. Greenberg, Barry D. (1995). The COOH-terminus of the Alzheimer amyloid Aβ peptide: Differences in length influence the process of amyloid deposition in Alzheimer brain, and

tell us something about relationships among parenchymal and vessel-associated amyloid deposits. Amyloid, 2(3): 195–203. doi:10.3109/13506129509036927.

78. Gunnar K. Gouras; Claudia G. Almeida; Reisuke H. Takahashi (2005). Intraneuronal Aβ accumulation and origin of plaques in Alzheimer's disease., 26(9): 0–1244. doi:10.1016/j.neurobiolaging.2005.05.022.
79. H. Bickel; K. Bürger; H. Hampel; Y. Schreiber; A. Sonntag; B. Wiegele; H. Förstl; A. Kurz (2006). Präsenile Demenzen in Gedächtnisambulanzen — Konsultationsinzidenz und Krankheitscharakteristika., 77(9): 1079–1085. doi:10.1007/s00115-005-1949-y.
80. H. Ferreira-Vieira, Talita; M. Guimaraes, Isabella; R. Silva, Flavia; M. Ribeiro, Fabiola (2016). Alzheimer's disease: Targeting the Cholinergic System. Current Neuropharmacology, 14(1): 101–115. doi:10.2174/1570159X13666150716165726
81. H. Steiner; A. Capell; U. Leimer; C. Haass (1999). Genes and mechanisms involved in β-amyloid generation and Alzheimer’s disease., 249(6): 266–270. doi:10.1007/s004060050098.
82. Haass, Christian; Selkoe, Dennis J. (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide., 8(2): 101–112. doi:10.1038/nrm2101.
83. Haass, Christian; Selkoe, Dennis J. (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide., 8(2): 101–112. doi:10.1038/nrm2101.
84. Hardy, J.; Higgins, G. (1992). Alzheimer's disease: the amyloid cascade hypothesis., 256(5054): 184–185. doi:10.1126/science.1566067.
85. Harris, J. Robin (2012). [Subcellular Biochemistry] Protein Aggregation and Fibrillogenesis in Cerebral and Systemic Amyloid Disease Volume 65 || Alzheimer’s Diseases., 10.1007/978-94-007-5416-4(Chapter 14): 329–352. doi:10.1007/978-94-007-5416-4_14.
86. Haruhiko Akiyama; Masato Hosokawa; Fuyuki Kametani; Hiromi Kondo; Momoko Chiba; Masako Fukushima; Takeshi Tabira (2012). Long-term oral intake of aluminium or zinc does not accelerate Alzheimer pathology in AβPP and AβPP/tau transgenic mice., 32(4): 0–0. doi:10.1111/j.1440-1789.2011.01274.x.
87. Haruhiko Akiyama; Steven Barger; Scott Barnum; Bonnie Bradt; Joachim Bauer; Greg M Cole; Neil R Cooper; Piet Eikelenboom; Mark Emmerling; Berndt L Fiebich; Caleb E Finch; Sally Frautschy; W.S.T Griffin; Harald Hampel; Michael Hull; Gary Landreth; Lih–Fen Lue; Robert Mrak; Ian R Mackenzie; Patrick L McGeer; M.Kerry O’Banion;

Joel Pachter; Guilio Pasinetti; Carlos Plata–Salaman; Joseph Rogers; Russell Rydel; Yong Shen; Wolfgang Streit; Ronald Strohmeyer; Ikuo Tooyoma; Freek L Van Muiswinkel; Robert Veerhuis; Douglas Walker; Scott Webster; Beatrice Wegrzyniak; Gary Wenk; Tony Wyss–Coray (2000). Inflammation and Alzheimer's disease., 21(3): 0–421. doi:10.1016/s0197-4580(00)00124-x.

88. Harvey, R J (2003). The prevalence and causes of dementia in people under the age of 65 years. Journal of Neurology, Neurosurgery & Psychiatry, 74(9): 1206–1209. doi:10.1136/jnnp.74.9.1206.
89. Hebert, L. E.; Weuve, J.; Scherr, P. A.; Evans, D. A. (2013). Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology, 80(19): 1778–1783. doi:10.1212/wnl.0b013e31828726f5.
90. Hedden, T.; Oh, H.; Younger, A. P.; Patel, T. A. (2013). Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology, 80(14): 1341–1348. doi:10.1212/WNL.0b013e31828ab35d.
91. Helen Hsieh; Jannic Boehm; Chihiro Sato; Takeshi Iwatsubo; Taisuke Tomita; Sangram Sisodia; Roberto Malinow (2006). AMPAR Removal Underlies Aβ-Induced Synaptic Depression and Dendritic Spine Loss., 52(5): 0–843. doi:10.1016/j.neuron.2006.10.035.
92. Henderson AS. The risk factors for Alzheimer's disease:a review and a hypothesis. Acta Psychiatr Scand 1988; 78: 257-275 doi:10.1111/j.1600-0447.1988.tb06336.x.
93. Henderson, V. W. (1997). The epidemiology of estrogen replacement therapy and Alzheimer's disease. Neurology, 48(Issue 5, Supplement 7): 27S–35S. doi:10.1212/wnl.48.5_suppl_7.27s.
94. Henry Brodaty; Monique M. B. Breteler; Steven T. DeKosky; Pascale Dorenlot; Laura Fratiglioni; Christoph Hock; Paul-Ariel Kenigsberg; Philip Scheltens; Bart De Strooper (2011). The World of Dementia Beyond 2020., 59(5): 923–927. doi:10.1111/j.1532-5415.2011.03365.x.
95. Hensley, K.; Carney, J. M.; Mattson, M. P.; Aksenova, M.; Harris, M.; Wu, J. F.; Floyd, R. A.; Butterfield, D. A. (1994). A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease.. Proceedings of the National Academy of Sciences, 91(8): 3270–3274. doi:10.1073/pnas.91.8.3270.
96. Hensley, K.; Carney, J. M.; Mattson, M. P.; Aksenova, M.; Harris, M.; Wu, J. F.; Floyd, R. A.; Butterfield, D. A. (1994). A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease..

Proceedings of the National Academy of Sciences, 91(8): 3270–3274. doi:10.1073/pnas.91.8.3270.

97. Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., … Smith, M. A. (2001). Mitochondrial Abnormalities in Alzheimer's Disease. The Journal of Neuroscience, 21(9): 3017–3023. doi:10.1523/jneurosci.21-09-03017.2001.
98. Holtzman, D. M.; Morris, J. C.; Goate, A. M. (2011). Alzheimer's Disease: The Challenge of the Second Century., 3(77): 77–77. doi:10.1126/scitranslmed.3002369.
99. Honarnejad, Kamran; Herms, Jochen (2012). Presenilins: Role in calcium homeostasis. The International Journal of Biochemistry & Cell Biology, 44(11): 1983–1986. doi:10.1016/j.biocel.2012.07.019.
100. Hsiao, Karen K.; Chapman, Paul F.; White, Gail L.; Jones, Matthew W.; Cooper-Blacketer, Deirdre; Marshall, Vanessa J.; Irizarry, Michael; Younkin, Linda; Good, Mark A.; Bliss, T. V. P.; Hyman, Bradley T.; Younkin, Steven G. (1999). . Nature Neuroscience, 2(3): 271–276. doi:10.1038/6374.
101. Hsu, Heng-Wei; Bondy, Stephen C; Kitazawa, Masashi (2018). Environmental and dietary exposure to copper and its cellular mechanisms linking to Alzheimer disease. Toxicological Sciences, doi:10.1093/toxsci/kfy025.
102. Huang, Yu-Jhen; Lin, Chieh-Hsin; Lane, Hsien-Yuan; E. Tsaid, Guochuan (2012). NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease. Current Neuropharmacology, 10(3): 272–285. doi:10.2174/157015912803217288
103. Humphries, Kenneth M.; Szweda, Luke I. (1998). Selective Inactivation of α-Ketoglutarate Dehydrogenase and Pyruvate Dehydrogenase: Reaction of Lipoic Acid with 4-Hydroxy-2-nonenal [†]. Biochemistry, 37(45): 15835–15841. doi:10.1021/bi981512h.
104. Huynh, Tien-Phat V.; Davis, Albert A.; Ulrich, Jason D.; Holtzman, David M. (2017). Apolipoprotein E and Alzheimer Disease: The influence of apoE on amyloid-β and other amyloidogenic proteins. Journal of Lipid Research, : jlr.R075481–. doi:10.1194/jlr.R075481.
105. Hy, L. X.; Keller, D. M. (2000). Prevalence of AD among whites: A summary by levels of severity. Neurology, 55(2): 198–204. doi:10.1212/WNL.55.2.198.
106. Hyoe Kanemitsu; Takami Tomiyama; Hiroshi Mori (2003). Human neprilysin is capable of degrading amyloid β peptide not only in the monomeric form but also the pathological oligomeric form., 350(2): 0–116. doi:10.1016/s0304-3940(03)00898-x.

107. Hyoung-gon Lee; George Perry; Paula I. Moreira; Matthew R. Garrett; Quan Liu; Xiongwei Zhu; Atsushi Takeda; Akihiko Nunomura; Mark A. Smith (2005). Tau phosphorylation in Alzheimer's disease: pathogen or protector?., 11(4): 0–169. doi:10.1016/j.molmed.2005.02.008.
108. Ian R. A. Mackenzie; Laurie A. Miller (1994). Senile plaques in temporal lobe epilepsy., 87(5): 504–510. doi:10.1007/bf00294177.
109. Ikonomovic, Milos D.; Wecker, Lynn; Abrahamson, Eric E.; Wuu, Joanne; Counts, Scott E.; Ginsberg, Stephen D.; Mufson, Elliott J.; DeKosky, Steven T. (2009). Cortical α7 Nicotinic Acetylcholine Receptor and β-Amyloid Levels in Early Alzheimer Disease. Archives of Neurology, 66(5): –. doi:10.1001/archneurol.2009.46.
110. Irwin, David J.; Trojanowski, John Q.; Grossman, Murray (2013). Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. Frontiers in Aging Neuroscience, 5 doi:10.3389/fnagi.2013.00006
111. Iwata, N. (2001). Metabolic Regulation of Brain Abeta by Neprilysin. Science, 292(5521): 1550–1552. doi:10.1126/science.1059946.
112. J. J. M. Hoozemans; R. Veerhuis; E. S. Van Haastert; J. M. Rozemuller; F. Baas; P. Eikelenboom; W. Scheper (2005). The unfolded protein response is activated in Alzheimer's disease., 110(2): 165–172. doi:10.1007/s00401-005-1038-0.
113. J. Rogers; L. C. Kirby; S. R. Hempelman; D. L. Berry; P. L. Mcgeer; A. W. Kaszniak; J. Zalinski; M. Cofield; L. Mansukhani; P. Willson; F. Kogan (1993). Clinical trial of indomethacin in Alzheimer's disease., doi:10.1212/WNL.43.8.1609.
114. J.N Keller; R.J Mark; A.J Bruce; E. Blanc; J.D Rothstein; K Uchida; G Waeg; M.P Mattson (1997). 4-Hydroxynonenal, an aldehydic product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synaptosomes., 80(3): 0–696. doi:10.1016/s0306-4522(97)00065-1.
115. Jack, Clifford R.; Wiste, Heather J.; Weigand, Stephen D.; Knopman, David S.; Vemuri, Prashanthi; Mielke, Michelle M.; Lowe, Val; Senjem, Matthew L.; Gunter, Jeffrey L.; Machulda, Mary M.; Gregg, Brian E.; Pankratz, V. Shane; Rocca, Walter A.; Petersen, Ronald C. (2015). Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span. JAMA Neurology, 72(5): 511–. doi:10.1001/jamaneurol.2014.4821.
116. Jack, Clifford R; Wiste, Heather J; Botha, Hugo; Weigand, Stephen D; Therneau, Terry M; Knopman, David S; Graff-Radford, Jonathan; Jones, David T; Ferman, Tanis J; Boeve, Bradley F; Kantarci, Kejal; Lowe, Val J; Vemuri, Prashanthi; Mielke, Michelle

M; Fields, Julie A; Machulda, Mary M; Schwarz, Christopher G; Senjem, Matthew L; Gunter, Jeffrey L; Petersen, Ronald C (2019). The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes. Brain, : awz268–. doi:10.1093/brain/awz268.

117. Jellinger, Kurt A. (2013). Pathology and pathogenesis of vascular cognitive impairment—a critical update. Frontiers in Aging Neuroscience, 5 doi:10.3389/fnagi.2013.00017.
118. John C.S. Breitner; Kathleen A. Welsh; Michael J. Helms; Perry C. Gaskell; Barbara A. Gau; Allen D. Roses; Margaret A. Pericak-Vance; Ann M. Saunders (1995). Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs., 16(4): 523–530. doi:10.1016/0197-4580(95)00049-k.
119. John D. Fisk; B. Lynn Beattie; Martha Donnelly; Anna Byszewski; Frank J. Molnar (2007). Disclosure of the diagnosis of dementia., 3(4): 404–410. doi:10.1016/j.jalz.2007.07.008
120. John Larson; Gary Lynch; Dora Games; Peter Seubert (1999). Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice., 840(1-2): 23–35. doi:10.1016/s0006-8993(99)01698-4.
121. John R. Cirrito; Kelvin A. Yamada; Mary Beth Finn; Robert S. Sloviter; Kelly R. Bales; Patrick C. May; Darryle D. Schoepp; Steven M. Paul; Steven Mennerick; David M. Holtzman (2005). Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo., 48(6): 0–922. doi:10.1016/j.neuron.2005.10.028.
122. Jones, D. T.; Machulda, M. M.; Vemuri, P.; McDade, E. M.; Zeng, G.; Senjem, M. L.; Gunter, J. L.; Przybelski, S. A.; Avula, R. T.; Knopman, D. S.; Boeve, B. F.; Petersen, R. C.; Jack, C. R. (2011). Age-related changes in the default mode network are more advanced in Alzheimer disease. Neurology, 77(16): 1524–1531. doi:10.1212/WNL.0b013e318233b33d.
123. Jorge Busciglio; Alejandra Pelsman; Caine Wong; Gustavo Pigino; Menglan Yuan; Hiroshi Mori; Bruce A. Yankner (2002). Altered Metabolism of the Amyloid β Precursor Protein Is Associated with Mitochondrial Dysfunction in Down's Syndrome., 33(5): 0–688. doi:10.1016/s0896-6273(02)00604-9.
124. Joseph L. Price; John C. Morris (1999). Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease., 45(3): 358–368. doi:10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x.
125. Joshi, Aditi; Ringman, John M.; Lee, Albert S.; Juarez, Kevin O.; Mendez, Mario F. (2012). Comparison of clinical characteristics between familial and non-familial early

onset Alzheimer's disease. Journal of Neurology, 259(10): 2182–2188. doi:10.1007/s00415-012-6481-y.

126. Julie A. Schneider; Zoe Arvanitakis; Sue E. Leurgans; David A. Bennett (2009). The neuropathology of probable Alzheimer disease and mild cognitive impairment., 66(2): 200–208. doi:10.1002/ana.21706.
127. Jungsu Kim; Jacob M. Basak; David M. Holtzman (2009). The Role of Apolipoprotein E in Alzheimer's Disease., 63(3): 0–303. doi:10.1016/j.neuron.2009.06.026.
128. Kadohara, K.; Sato, I.; Kawakami, K. (2017). Diabetes mellitus and risk of early-onset Alzheimer's disease: a population-based case-control study. European Journal of Neurology, doi:10.1111/ene.13312.
129. Kapasi, Alifiya; DeCarli, Charles; Schneider, Julie A. (2017). Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathologica, doi:10.1007/s00401-017-1717-7.
130. Karanth, Shama; Nelson, Peter T.; Katsumata, Yuriko; Kryscio, Richard J.; Schmitt, Frederick A.; Fardo, David W.; Cykowski, Matthew D.; Jicha, Gregory A.; Van Eldik, Linda J.; Abner, Erin L. (2020). Prevalence and Clinical Phenotype of Quadruple Misfolded Proteins in Older Adults. JAMA Neurology, doi:10.1001/jamaneurol.2020.1741.
131. Kawas, C.; Resnick, S.; Morrison, A.; Brookmeyer, R.; Corrada, M.; Zonderman, A.; Bacal, C.; Lingle, D. D.; Metter, E. (1997). A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology, 48(6): 1517–1521. doi:10.1212/WNL.48.6.1517.
132. Kayed, R. (2003). Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis. Science, 300(5618): 486–489. doi:10.1126/science.1079469.
133. Kennard, Malcolm L.; Feldman, Howard; Yamada, Tatsuo; Jefferies, Wilfred A. (1996). Serum levels of the iron binding protein p97 are elevated in Alzheimer′s disease., 2(11): 1230–1235. doi:10.1038/nm1196-1230.
134. Khalid Iqbal; Alejandra del C. Alonso; She Chen; M. Omar Chohan; Ezzat El-Akkad; Cheng-Xin Gong; Sabiha Khatoon; Bin Li; Fei Liu; Abdur Rahman; Hitoshi Tanimukai; Inge Grundke-Iqbal (2005). Tau pathology in Alzheimer disease and other tauopathies., 1739(2-3): 0–210. doi:10.1016/j.bbadis.2004.09.008
135. Khlistunova, I. (2005). Inducible Expression of Tau Repeat Domain in Cell Models of Tauopathy: AGGREGATION IS TOXIC TO CELLS BUT CAN BE REVERSED BY INHIBITOR DRUGS., 281(2): 1205–1214. doi:10.1074/jbc.m507753200.

136. Khoury, Rita; Rajamanickam, Jayashree; Grossberg, George T. (2018). An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine. Therapeutic Advances in Drug Safety, : 204209861775055–. doi:10.1177/2042098617750555
137. Klyubin, I.; Betts, V.; Welzel, A. T.; Blennow, K.; Zetterberg, H.; Wallin, A.; Lemere, C. A.; Cullen, W. K.; Peng, Y.; Wisniewski, T.; Selkoe, D. J.; Anwyl, R.; Walsh, D. M.; Rowan, M. J. (2008). Amyloid Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization. Journal of Neuroscience, 28(16): 4231–4237. doi:10.1523/JNEUROSCI.5161-07.2008.
138. Koedam, Esther L.G.E.; Pijnenburg, Yolande A.L.; Deeg, Dorly J.H.; Baak, Merel M.E.; van der Vlies, Annelies E.; Scheltens, Philip; van der Flier, Wiesje M. (2008). Early-Onset Dementia Is Associated with Higher Mortality. Dementia and Geriatric Cognitive Disorders, 26(2): 147–152. doi:10.1159/000149585.
139. Kovari, E.; Herrmann, F. R.; Bouras, C.; Gold, G. (2014). Amyloid deposition is decreasing in aging brains: An autopsy study of 1,599 older people. Neurology, 82(4): 326–331. doi:10.1212/wnl.0000000000000069.
140. Koyama, Alain; Okereke, Olivia I.; Yang, Ting; Blacker, Deborah; Selkoe, Dennis J.; Grodstein, Francine (2012). Plasma Amyloid-β as a Predictor of Dementia and Cognitive Decline. Archives of Neurology, 69(7): –. doi:10.1001/archneurol.2011.1841
141. Lambert, M. A.; Bickel, H.; Prince, M.; Fratiglioni, L.; Von Strauss, E.; Frydecka, D.; Kiejna, A.; Georges, J.; Reynish, E. L. (2014). Estimating the burden of early onset dementia; systematic review of disease prevalence. European Journal of Neurology, 21(4): 563–569. doi:10.1111/ene.12325.
142. Lars Lannfelt; Kaj Blennow; Henrik Zetterberg; Stellan Batsman; David Ames; John Harrison; Colin L Masters; Steve Targum; Ashley I Bush; Ross Murdoch; Janet Wilson; Craig W Ritchie (2008). Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial., 7(9): 779–786. doi:10.1016/s1474-4422(08)70167-4.
143. Lawrence M. Sayre; Dawn A. Zelasko; Peggy L. R. Harris; George Perry; Robert G. Salomon; Mark A. Smith (1997). 4-Hydroxynonenal-Derived Advanced Lipid Peroxidation End Products Are Increased in Alzheimer's Disease., 68(5): 2092–2097. doi:10.1046/j.1471-4159.1997.68052092.x.
144. Le, Ricky; Cruz, Luis; Urbanc, Brigita; Knowles, Roger B.; Hsiao-Ashe, Karen; Duff, Karen; Irizarry, Michael C.; Stanley, H. Eugene; Hyman, Bradley T. (2001). Plaque-Induced Abnormalities in Neurite Geometry in Transgenic Models of Alzheimer Disease:

Implications for Neural System Disruption. Journal of Neuropathology & Experimental Neurology, 60(8): 753–758. doi:10.1093/jnen/60.8.753.

145. Lee, Virginia M-Y; Goedert, Michel; Trojanowski, John Q (2001). N <scp>EURODEGENERATIVE</scp> T <scp>AUOPATHIES</scp>. Annual Review of Neuroscience, 24(1): 1121–1159. doi:10.1146/annurev.neuro.24.1.1121
146. Leonardo C. de Souza; Marie Chupin; Foudil Lamari; Claude Jardel; Delphine Leclercq; Olivier Colliot; Stéphane Lehéricy; Bruno Dubois; Marie Sarazin (2012). CSF tau markers are correlated with hippocampal volume in Alzheimer's disease., 33(7): 0–. doi:10.1016/j.neurobiolaging.2011.02.022.
147. Lewis, J. (2001). Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP. Science, 293(5534): 1487–1491. doi:10.1126/science.1058189.
148. Li, Yuekui; Liu, Ling; Barger, Steven W.; Griffin, W. Sue T. (2003). Interleukin-1 Mediates Pathological Effects of Microglia on Tau Phosphorylation and on Synaptophysin Synthesis in Cortical Neurons through a p38-MAPK Pathway. The Journal of Neuroscience, 23(5): 1605–1611. doi:10.1523/JNEUROSCI.23-05-01605.2003.
149. Lih-Fen Lue; Yu-Min Kuo; Alex E. Roher; Libuse Brachova; Yong Shen; Lucia Sue; Thomas Beach; Janice H. Kurth; Russel E. Rydel; Joseph Rogers (1999). Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease., 155(3): 0–862. doi:10.1016/s0002-9440(10)65184-x.
150. Lister, James P.; Barnes, Carol A. (2009). Neurobiological Changes in the Hippocampus During Normative Aging. Archives of Neurology, 66(7): –. doi:10.1001/archneurol.2009.125.
151. Liu, Guiyou; Yao, Lifen; Liu, Jiafeng; Jiang, Yongshuai; Ma, Guoda; Chen, Zugen; Zhao, Bin; Li, Keshen (2014). Cardiovascular disease contributes to Alzheimer's disease: evidence from large-scale genome-wide association studies. Neurobiology of Aging, 35(4): 786–792. doi:10.1016/j.neurobiolaging.2013.10.084.
152. Lleó, Alberto; Berezovska, Oksana; Herl, Lauren; Raju, Susan; Deng, Amy; Bacskai, Brian J; Frosch, Matthew P; Irizarry, Michael; Hyman, Bradley T (2004). Nonsteroidal anti-inflammatory drugs lower Aβ42 and change presenilin 1 conformation., 10(10): 1065–1066. doi:10.1038/nm1112.
153. Lui JK, Laws SM, Li QX, Villemagne VL, Ames D, BrownB, Bush AI, De Ruyck K, Dromey J, Ellis KA, Faux NG,Foster J, Fowler C, Gupta V, Hudson P, Laughton K, Masters CL, Pertile K, Rembach A, Rimajova M, Rodrigues M, Rowe CC, Rumble R,

Szoeke C, Taddei K, Taddei T,Trounson B,Ward V, Martins RN, Group AR (2010) Plasma amyloid-beta as a biomarker in Alzheimer's disease: The AIBL study of aging. J Alzheimers Dis 20, 1233-1242.doi:10.3233/JAD-141497.

154. Lustbader, J. W. (2004). ABAD Directly Links A to Mitochondrial Toxicity in Alzheimer's Disease., 304(5669): 448–452. doi:10.1126/science.1091230.
155. M.A Kurt; D.C Davies; M Kidd; K Duff; D.R Howlett (2003). Hyperphosphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes., 14(1): 0–97. doi:10.1016/s0969-9961(03)00084-6.
156. M.A Lovell; J.D Robertson; W.J Teesdale; J.L Campbell; W.R Markesbery (1998). Copper, iron and zinc in Alzheimer's disease senile plaques., 158(1): 47–52. doi:10.1016/s0022-510x(98)00092-6.
157. Mackenzie, I. R.A.; Munoz, D. G. (1998). Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology, 50(4): 986–990. doi:10.1212/wnl.50.4.986.
158. Malcolm A Leissring; Wesley Farris; Alice Y Chang; Dominic M Walsh; Xining Wu; Xiaoyan Sun; Matthew P Frosch; Dennis J Selkoe (2003). Enhanced Proteolysis of β-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death., 40(6): 0–1093. doi:10.1016/s0896-6273(03)00787-6.
159. Mariella López Salon; Laura Morelli; Eduardo M. Castaño; Eduardo F. Soto; Juana M. Pasquini (2000). Defective ubiquitination of cerebral proteins in Alzheimer's disease., 62(2): 302–310. doi:10.1002/1097-4547(20001015)62:2<302::aid-jnr15>3.0.co;2-l.
160. Mark A. Smith; Lawrence M. Sayre; Vincent M. Monnier; George Perry (1995). Radical AGEing in Alzheimer's disease., 18(4): 0–176. doi:10.1016/0166-2236(95)93897-7.
161. Mark, Robert J.; Pang, Zhen; Geddes, James W.; Uchida, Koji; Mattson, Mark P. (1997). Amyloid β-Peptide Impairs Glucose Transport in Hippocampal and Cortical Neurons: Involvement of Membrane Lipid Peroxidation. The Journal of Neuroscience, 17(3): 1046–1054. doi:10.1523/jneurosci.17-03-01046.1997.
162. Marni E. Harris; Kenneth Hensley; D.Allan Butterfield; Robert A. Leedle; John M. Carney (1995). Direct evidence of oxidative injury produced by the Alzheimer's β-Amyloid peptide (1–40) in cultured hippocampal neurons., 131(2): 0–202. doi:10.1016/0014-4886(95)90041-1.
163. Marottoli, Felecia M.; Katsumata, Yuriko; Koster, Kevin P.; Thomas, Riya; Fardo, David W.; Tai, Leon M. (2017). Peripheral Inflammation, Apolipoprotein E4, and

Amyloid-β Interact to Induce Cognitive and Cerebrovascular Dysfunction. ASN Neuro, 9(4): 175909141771920–. doi:10.1177/1759091417719201.

164. Masliah, E.; Mallory, M.; Alford, M.; DeTeresa, R.; Hansen, L.A.; McKeel, D.W.; Morris, J.C. (2001). Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology, 56(1): 127–129. doi:10.1212/WNL.56.1.127.
165. Masliah, Eliezer; Crews, Leslie; Hansen, Lawrence (2006). Synaptic remodeling during aging and in Alzheimer's disease. Journal of Alzheimer's Disease, 9(s3): 91–99. doi:10.3233/JAD-2006-9S311.
166. Math P. Cuajungco; Kyle Y. Fagét (2003). Zinc takes the center stage: its paradoxical role in Alzheimer’s disease., 41(1): 0–56. doi:10.1016/s0165-0173(02)00219-9.
167. Matsumoto, Yasuko; Yanase, Daisuke; Noguchi-Shinohara, Moeko; Ono, Kenjiro; Yoshita, Mitsuhiro; Yamada, Masahito (2007). Blood-Brain Barrier Permeability Correlates with Medial Temporal Lobe Atrophy but Not with Amyloid-β Protein Transport across the Blood-Brain Barrier in Alzheimer’s Disease. Dementia and Geriatric Cognitive Disorders, 23(4): 241–245. doi:10.1159/000100019
168. Mattsson, Niklas (2009). CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. JAMA, 302(4): 385–. doi:10.1001/jama.2009.1064.
169. Maurer K, Volk S, Gerbaldo H. Auguste D and Alzheimer’s disease. Lancet 1997;349(9064): 1546–1549. doi:10.1016/S0140-6736(96)10203-8. [PubMed] [CrossRef] [Google Scholar].
170. McCord, Meghan C.; Aizenman, Elias (2014). The role of intracellular zinc release in aging, oxidative stress, and Alzheimerâ€™s disease. Frontiers in Aging Neuroscience, 6 doi:10.3389/fnagi.2014.00077.
171. McGeer, P. L.; Schulzer, M.; McGeer, E. G. (1996). Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology, 47(2): 425–432. doi:10.1212/wnl.47.2.425.
172. McLaurin, JoAnne; Kierstead, Meredith E; Brown, Mary E; Hawkes, Cheryl A; Lambermon, Mark H L; Phinney, Amie L; Darabie, Audrey A; Cousins, Julian E; French, Janet E; Lan, Melissa F (2006). Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model., 12(7): 801–808. doi:10.1038/nm1423.
173. Mendez, M. F. (2019). Early-onset Alzheimer Disease and Its Variants. CONTINUUM: Lifelong Learning in Neurology, 25(1): 34–51. doi:10.1212/con.0000000000000687

174. Mendez, M. F. (2019). Early-onset Alzheimer Disease and Its Variants. CONTINUUM: Lifelong Learning in Neurology, 25(1): 34–51. doi:10.1212/con.0000000000000068.
175. Mendez, Mario F.; Paholpak, Pongsatorn; Lin, Andrew; Zhang, Jeannie Y.; Teng, Edmond; Alves, Tania (2015). Prevalence of Traumatic Brain Injury in Early Versus Late-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 47(4): 985–993. doi:10.3233/jad-143207.
176. Miroslaw Brys; Elizabeth Pirraglia; Kenneth Rich; Sindre Rolstad; Lisa Mosconi; Remigiusz Switalski; Lidia Glodzik-Sobanska; Susan De Santi; Ray Zinkowski; Pankaj Mehta; Domenico Pratico; Leslie A. Saint Louis; Anders Wallin; Kaj Blennow; Mony J. de Leon (2009). Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment., 30(5): 0–690. doi:10.1016/j.neurobiolaging.2007.08.010.
177. Moghekar, A.; Li, S.; Lu, Y.; Li, M.; Wang, M.-C.; Albert, M.; O'Brien, R. (2013). CSF biomarker changes precede symptom onset of mild cognitive impairment. Neurology, 81(20): 1753–1758. doi:10.1212/01.wnl.0000435558.98447.17.
178. Moschetti K, Barragan N, Basurto-Dávila R, et al. Mortality and productivity losses from Alzheimer disease among US adults aged 40 to 64 years, 1999 to 2010. Alzheimer Dis Assoc Disord 2015;29(2):165–168. doi:10.1097/WAD.0000000000000017.
179. Mrak, Robert E.; Griffin, W. Sue T. (2006). Potential Inflammatory biomarkers in Alzheimer's disease. Journal of Alzheimer's Disease, 8(4): 369–375. doi:10.3233/JAD-2005-8406
180. Mucke, Lennart; Masliah, Eliezer; Yu, Gui-Qiu; Mallory, Margaret; Rockenstein, Edward M.; Tatsuno, Gwen; Hu, Kang; Kholodenko, Dora; Johnson-Wood, Kelly; McConlogue, Lisa (2000). High-Level Neuronal Expression of Aβ _{1–42} in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation. The Journal of Neuroscience, 20(11): 4050–4058. doi:10.1523/jneurosci.20-11-04050.2000.
181. Mukta Dooley, Harriet M. Lamb (2000). Donepezil., 16(3): 199–226. doi:10.2165/00002512-200016030-0000
182. Müller, Ulrike C.; Deller, Thomas; Korte, Martin (2017). Not just amyloid: physiological functions of the amyloid precursor protein family. Nature Reviews Neuroscience, 18(5): 281–298. doi:10.1038/nrn.2017.29
183. Mutter, J.; Naumann, J.; Schneider, R.; Walach, H. (2007). Quecksilber und Alzheimer-Erkrankung. Fortschritte der Neurologie · Psychiatrie, 75(9): 528–538. doi:10.1055/s-2007-959237.

184. Nagahara, Alan H; Merrill, David A; Coppola, Giovanni; Tsukada, Shingo; Schroeder, Brock E; Shaked, Gideon M; Wang, Ling; Blesch, Armin; Kim, Albert; Conner, James M (2009). Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease., 15(3): 331–337. doi:10.1038/nm.1912.
185. Ngandu, Tiia; Lehtisalo, Jenni; Solomon, Alina; Levälahti, Esko; Ahtiluoto, Satu; Antikainen, Riitta; Bäckman, Lars; Hänninen, Tuomo; Jula, Antti; Laatikainen, Tiina; Lindström, Jaana; Mangialasche, Francesca; Paajanen, Teemu; Pajala, Satu; Peltonen, Markku; Rauramaa, Rainer; Stigsdotter-Neely, Anna; Strandberg, Timo; Tuomilehto, Jaakko; Soininen, Hilkka; Kivipelto, Miia (2015). A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. The Lancet, 385(9984): 2255–2263. doi:10.1016/S0140-6736(15)60461-5.
186. Niu, H.; Álvarez-Álvarez, I.; Guillén-Grima, F.; Aguinaga-Ontoso, I. (2016). Prevalencia e incidencia de la enfermedad de Alzheimer en Europa: metaanálisis. Neurología, : S0213485316300032–. doi:10.1016/j.nrl.2016.02.016.
187. Notarachille, Gabriella; Arnesano, Fabio; Calò, Vincenza; Meleleo, Daniela (2014). Heavy metals toxicity: effect of cadmium ions on amyloid beta protein 1–42. Possible implications for Alzheimer's disease. BioMetals, 27(2): 371–388. doi:10.1007/s10534-014-9719-6.
188. Nunomura, Akihiko; Perry, George; Aliev, Gjumrakch; Hirai, Keisuke; Takeda, Atsushi; Balraj, Elizabeth K.; Jones, Paul K.; Ghanbari, Hossein; Wataya, Takafumi; Shimohama, Shun; Chiba, Shigeru; Atwood, Craig S.; Petersen, Robert B.; Smith, Mark A. (2001). Oxidative Damage Is the Earliest Event in Alzheimer Disease. Journal of Neuropathology & Experimental Neurology, 60(8): 759–767. doi:10.1093/jnen/60.8.759 .
189. Oddo, S.; Vasilevko, V.; Caccamo, A.; Kitazawa, M.; Cribbs, D. H.; LaFerla, F. M. (2006). Reduction of Soluble Abeta and Tau, but Not Soluble Abeta Alone, Ameliorates Cognitive Decline in Transgenic Mice with Plaques and Tangles. Journal of Biological Chemistry, 281(51): 39413–39423. doi:10.1074/jbc.M608485200.
190. Ono, K.; Condron, M. M.; Ho, L.; Wang, J.; Zhao, W.; Pasinetti, G. M.; Teplow, D. B. (2008). Effects of Grape Seed-derived Polyphenols on Amyloid -Protein Self-assembly and Cytotoxicity. Journal of Biological Chemistry, 283(47): 32176–32187. doi:10.1074/jbc.M806154200.
191. Oskar Hansson; Henrik Zetterberg; Eugeen Vanmechelen; Hugo Vanderstichele; Ulf Andreasson; Elisabet Londos; Anders Wallin; Lennart Minthon; Kaj Blennow (2010).

Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment., 31(3): 0–367. doi:10.1016/j.neurobiolaging.2008.03.027

192. Ossenkoppele, Rik; Schonhaut, Daniel R.; Schöll, Michael; Lockhart, Samuel N.; Ayakta, Nagehan; Baker, Suzanne L.; O'Neil, James P.; Janabi, Mustafa; Lazaris, Andreas; Cantwell, Averill; Vogel, Jacob; Santos, Miguel; Miller, Zachary A.; Bettcher, Brianne M.; Vossel, Keith A.; Kramer, Joel H.; Gorno-Tempini, Maria L.; Miller, Bruce L.; Jagust, William J.; Rabinovici, Gil D. (2016). Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain, : aww027–. doi:10.1093/brain/aww027.
193. P. Hemachandra Reddy; M. Flint Beal (2008). Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease., 14(2): 0–53. doi:10.1016/j.molmed.2007.12.002.
194. Pal A, Siotto M, Prasad R, Squitti R. Towards a unified vision of copper involvement in Alzheimer's disease: A review connectFolia Neuropathologica 2019; 57/2 103Risk factors for Alzheimer's diseaseing basic, experimental, and clinical research. J Alz Dis 2015;44: 343-354. doi:10.3233/jad-141194.
195. Palasí, Antonio; Gutiérrez-Iglesias, Belén; Alegret, Montse; Pujadas, Francesc; Olabarrieta, Mikel; Liébana, Diana; Quintana, Manolo; Álvarez-Sabín, José; Boada, Mercè (2015). Differentiated clinical presentation of early and late-onset Alzheimer's disease: is 65 years of age providing a reliable threshold?. Journal of Neurology, 262(5): 1238–1246. doi:10.1007/s00415-015-7698-3.
196. Patrick L. McGeer; Edith G. McGeer (1995). The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases., 21(2): 0–218. doi:10.1016/0165-0173(95)00011-9.
197. Patrick L. McGeer; Edith G. McGeer (2007). NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies., 28(5): 0–647. doi:10.1016/j.neurobiolaging.2006.03.013.
198. Patrik Ernfors; Clive R. Bramham (2003). The coupling of a trkB tyrosine residue to LTP., 26(4): 0–173. doi:10.1016/s0166-2236(03)00064-x.
199. Peltz, C. B.; Corrada, M. M.; Berlau, D. J.; Kawas, C. H. (2011). Incidence of dementia in oldest-old with amnestic MCI and other cognitive impairments. Neurology, 77(21): 1906–1912. doi:10.1212/WNL.0b013e318238ee89.

200. Peter M. Clifford; Shabnam Zarrabi; Gilbert Siu; Kristin J. Kinsler; Mary C. Kosciuk; Venkateswar Venkataraman; Michael R. D'Andrea; Steven Dinsmore; Robert G. Nagele (2007). Aβ peptides can enter the brain through a defective blood–brain barrier and bind selectively to neurons., 1142(none): 223–236. doi:10.1016/j.brainres.2007.01.070.
201. Peter T. Nelson; Elizabeth Head; Frederick A. Schmitt; Paulina R. Davis; Janna H. Neltner; Gregory A. Jicha; Erin L. Abner; Charles D. Smith; Linda J. Van Eldik; Richard J. Kryscio; Stephen W. Scheff (2011). Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies., 121(5): 571–587. doi:10.1007/s00401-011-0826-y.
202. Peters, S.; Reid, A.; Fritschi, L.; de Klerk, N.; Musk, A. W. (2013). Long-term effects of aluminium dust inhalation. Occupational and Environmental Medicine, 70(12): 864–868. doi:10.1136/oemed-2013-101487.
203. Petersen, Ronald C.; Aisen, Paul; Boeve, Bradley F.; Geda, Yonas E.; Ivnik, Robert J.; Knopman, David S.; Mielke, Michelle; Pankratz, Vernon S.; Roberts, Rosebud; Rocca, Walter A.; Weigand, Stephen; Weiner, Michael; Wiste, Heather; Jack, Clifford R. (2013). Criteria for mild cognitive impairment due to alzheimer's disease in the community. Annals of Neurology, : n/a–n/a. doi:10.1002/ana.23931.
204. Petersen, Ronald C.; Lopez, Oscar; Armstrong, Melissa J.; Getchius, Thomas S.D.; Ganguli, Mary; Gloss, David; Gronseth, Gary S.; Marson, Daniel; Pringsheim, Tamara; Day, Gregory S.; Sager, Mark; Stevens, James; Rae-Grant, Alexander (2017). Practice guideline update summary: Mild cognitive impairment. Neurology, : 10.1212/WNL.0000000000004826–. doi:10.1212/WNL.0000000000004826.
205. Pinar Coskun; Joanne Wyrembak; Samual E. Schriner; Hsiao-Wen Chen; Christine Marciniack; Frank LaFerla; Douglas C. Wallace (2012). A mitochondrial etiology of Alzheimer and Parkinson disease., 1820(5): 0–564. doi:10.1016/j.bbagen.2011.08.008
206. Podlesniy, Petar; Figueiro-Silva, Joana; Llado, Albert; Antonell, Anna; Sanchez-Valle, Raquel; Alcolea, Daniel; Lleo, Alberto; Molinuevo, Jose Luis; Serra, Nuria; Trullas, Ramon (2013). Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. Annals of Neurology, 74(5): 655–668. doi:10.1002/ana.23955
207. Pooler, Amy M.; Noble, Wendy; Hanger, Diane P. (2014). A role for tau at the synapse in Alzheimer's disease pathogenesis. Neuropharmacology, 76 : 1–8. doi:10.1016/j.neuropharm.2013.09.018.

208. Prince, Martin; Ali, Gemma-Claire; Guerchet, Maëlenn; Prina, A. Matthew; Albanese, Emiliano; Wu, Yu-Tzu (2016). Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimer's Research & Therapy, 8(1): 23–. doi:10.1186/s13195-016-0188-8.
209. Qiu, W. Q. (1998). Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid beta -Protein by Degradation. Journal of Biological Chemistry, 273(49): 32730–32738. doi:10.1074/jbc.273.49.32730.
210. R.A. Armstrong; S.J. Winsper; J.A. Blair (1995). Hypothesis: is Alzheimer's Disease a Metal-induced Immune Disorder?., 4(1): 0–111. doi:10.1006/neur.1995.0013
211. Rachelle S Doody; Svetlana I Gavrilova; Mary Sano; Ronald G Thomas; Paul S Aisen; Sergey O Bachurin; Lynn Seely; David Hung (2008). Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study., 372(9634): 0–215. doi:10.1016/s0140-6736(08)61074-0.
212. Radosveta Koldamova; Nicholas F. Fitz; Iliya Lefterov (2010). The role of ATP-binding cassette transporter A1 in Alzheimer's disease and neurodegeneration., 1801(8): 0–830. doi:10.1016/j.bbalip.2010.02.010,
213. Ralph A. Nixon; Dun-Sheng Yang (2011). Autophagy failure in Alzheimer's disease—locating the primary defect., 43(1): 38–45. doi:10.1016/j.nbd.2011.01.021.
214. Rapoport SI, Pettigrew KD, Schapiro MB. Discordance and concordance of dementia of the Alzheimer type (DAT) in monozygotic twins indicate heritable and sporadic forms of Alzheimer’s disease. Neurology 1991;41:1549-53. doi:10.1212/wnl.41.10.1549.
215. Rapoport, M.; Dawson, H. N.; Binder, L. I.; Vitek, M. P.; Ferreira, A. (2002). Tau is essential to -amyloid-induced neurotoxicity. Proceedings of the National Academy of Sciences, 99(9): 6364–6369. doi:10.1073/pnas.092136199.
216. Rathmann, K. L.; Conner, C. S. (1984). Alzheimer's Disease: Clinical Features, Pathogenesis, and Treatment. Annals of Pharmacotherapy, 18(9): 684–691. doi:10.1177/106002808401800902.
217. Reiman, E. M.; Chen, K.; Liu, X.; Bandy, D.; Yu, M.; Lee, W.; Ayutyanont, N.; Keppler, J.; Reeder, S. A.; Langbaum, J. B. S.; Alexander, G. E.; Klunk, W. E.; Mathis, C. A.; Price, J. C.; Aizenstein, H. J.; DeKosky, S. T.; Caselli, R. J. (2009). Fibrillar amyloid-burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proceedings of the National Academy of Sciences, 106(16): 6820–6825. doi:10.1073/pnas.0900345106.

218. Rembach, Alan; Faux, Noel G.; Watt, Andrew D.; Pertile, Kelly K.; Rumble, Rebecca L.; Trounson, Brett O.; Fowler, Christopher J.; Roberts, Blaine R.; Perez, Keyla A.; Li, Qiao-Xin; Laws, Simon M.; Taddei, Kevin; Rainey-Smith, Stephanie; Robertson, Joanne S.; Vandijck, Manu; Vanderstichele, Hugo; Barnham, Kevin J.; Ellis, Kathryn A.; Szoeke, Cassandra; Macaulay, Lance; Rowe, Christopher C.; Villemagne, Victor L.; Ames, David; Martins, Ralph N.; Bush, Ashley I.; Masters, Colin L. (2014). Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimer's & Dementia, 10(1): 53–61. doi:10.1016/j.jalz.2012.12.006.
219. Reuben, David B.; Gill, Thomas M.; Stevens, Alan; Williamson, Jeff; Volpi, Elena; Lichtenstein, Maya; Jennings, Lee A.; Tan, Zaldy; Evertson, Leslie; Bass, David; Weitzman, Lisa; Carnie, Martie; Wilson, Nancy; Araujo, Katy; Charpentier, Peter; Meng, Can; Greene, Erich J.; Dziura, James; Liu, Jodi; Unger, Erin; Yang, Mia; Currie, Katherine; Lenoir, Kristin M.; Green, Avalâ€ • Na'Ree S.; Abraham, Sitara; Vernon, Ashley; Samperâ€ • Ternent, Rafael; Raji, Mukaila; Hirst, Roxana M.; Galloway, Rebecca; Finney, Glen R.; Ladd, Ilene; Rahm, Alanna Kulchak; Borek, Pamela; Peduzzi, Peter (2020). <scp>Dâ€ • CARE</scp> â€ • The Dementia Care Study: Design of a Pragmatic Trial of the Effectiveness and Costâ€ • effectiveness of Health Systemâ€ • based versus Communityâ€ • based Dementia Care versus Usual Dementia Care. Journal of the American Geriatrics Society, : jgs.16862–. doi:10.1111/jgs.16862.
220. Rice, Heather C.; de Malmazet, Daniel; Schreurs, An; Frere, Samuel; Van Molle, Inge; Volkov, Alexander N.; Creemers, Eline; Vertkin, Irena; Nys, Julie; Ranaivoson, Fanomezana M.; Comoletti, Davide; Savas, Jeffrey N.; Remaut, Han; Balschun, Detlef; Wierda, Keimpe D.; Slutsky, Inna; Farrow, Karl; De Strooper, Bart; de Wit, Joris (2019). Secreted amyloid-β precursor protein functions as a GABA _B R1a ligand to modulate synaptic transmission. Science, 363(6423): eaao4827–. doi:10.1126/science.aao4827.
221. Ringman, J. M.; Younkin, S. G.; Pratico, D.; Seltzer, W.; Cole, G. M.; Geschwind, D. H.; Rodriguez-Agudelo, Y.; Schaffer, B.; Fein, J.; Sokolow, S.; Rosario, E. R.; Gylys, K. H.; Varpetian, A.; Medina, L. D.; Cummings, J. L. (2008). Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology, 71(2): 85–92. doi:10.1212/01.wnl.0000303973.71803.81
222. Ringman, John M.; Coppola, Giovanni; Elashoff, David; Rodriguez-Agudelo, Yaneth; Medina, Luis D.; Gylys, Karen; Cummings, Jeffrey L.; Cole, Greg M. (2012). Cerebrospinal Fluid Biomarkers and Proximity to Diagnosis in Preclinical Familial

Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 33(1): 1–5. doi:10.1159/000335729.

223. Robb, Melissa A.; McInnes, Pamela M.; Califf, Robert M. (2016). Biomarkers and Surrogate Endpoints. JAMA, 315(11): 1107–. doi:10.1001/jama.2016.2240.
224. Roberson, E. D.; Scearce-Levie, K.; Palop, J. J.; Yan, F.; Cheng, I. H.; Wu, T.; Gerstein, H.; Yu, G.-Q.; Mucke, L. (2007). Reducing Endogenous Tau Ameliorates Amyloid -Induced Deficits in an Alzheimer's Disease Mouse Model. Science, 316(5825): 750–754. doi:10.1126/science.1141736.
225. Robert S. Bitner; Arthur L. Nikkel; Stella Markosyan; Stephani Otte; Pamela Puttfarcken; Murali Gopalakrishnan (2009). Selective α7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3β and decreases tau phosphorylation in vivo., 1265(none): 65–74. doi:10.1016/j.brainres.2009.01.069.
226. Robin W Carrell; David A Lomas (1997). Conformational disease., 350(9071): 134–138. doi:10.1016/s0140-6736(97)02073-4.
227. Robinson, John L; Lee, Edward B; Xie, Sharon X; Rennert, Lior; Suh, EunRan; Bredenberg, Colin; Caswell, Carrie; Van Deerlin, Vivianna M; Yan, Ning; Yousef, Ahmed; Hurtig, Howard I; Siderowf, Andrew; Grossman, Murray; McMillan, Corey T; Miller, Bruce; Duda, John E; Irwin, David J; Wolk, David; Elman, Lauren; McCluskey, Leo; Chen-Plotkin, Alice; Weintraub, Daniel; Arnold, Steven E; Brettschneider, Johannes; Lee, Virginia M-Y; Trojanowski, John Q (2018). Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain, doi:10.1093/brain/awy146.
228. Roe, C. M.; Fagan, A. M.; Grant, E. A.; Hassenstab, J.; Moulder, K. L.; Maue Dreyfus, D.; Sutphen, C. L.; Benzinger, T. L. S.; Mintun, M. A.; Holtzman, D. M.; Morris, J. C. (2013). Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology, 80(19): 1784–1791. doi:10.1212/wnl.0b013e3182918ca6
229. Roger M. Nitsch (1996). From Acetylcholine to Amyloid: Neurotransmitters and the Pathology of Alzheimer's Disease., 5(4): 477–482. doi:10.1006/neur.1996.0066.
230. Rudolph E. Tanzi; Lars Bertram (2005). Twenty Years of the Alzheimer's Disease Amyloid Hypothesis: A Genetic Perspective., 120(4): 0–555. doi:10.1016/j.cell.2005.02.008.
231. Sally G. Haskell; Emily D. Richardson; Ralph I. Horwitz (1997). The effect of estrogen replacement therapy on cognitive function in women: A critical review of the literature., 50(11): 0–1264. doi:10.1016/s0895-4356(97)00169-8.

232. Salvatore Oddo; Antonella Caccamo; Jason D Shepherd; M.Paul Murphy; Todd E Golde; Rakez Kayed; Raju Metherate; Mark P Mattson; Yama Akbari; Frank M LaFerla (2003). Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles: Intracellular Aβ and Synaptic Dysfunction., 39(3): 0–421. doi:10.1016/s0896-6273(03)00434-3.
233. Salvatore Salomone; Filippo Caraci; Gian Marco Leggio; Julia Fedotova; Filippo Drago (2012). New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs., 73(4): 504–517. doi:10.1111/j.1365-2125.2011.04134.x
234. Sandra M. Cardoso; Isabel Santana; Russell H. Swerdlow; Catarina R. Oliveira (2004). Mitochondria dysfunction of Alzheimer's disease cybrids enhances Aβ toxicity., 89(6): 1417–1426. doi:10.1111/j.1471-4159.2004.02438.x.
235. Sano, Mary; Ernesto, Christopher; Thomas, Ronald G.; Klauber, Melville R.; Schafer, Kimberly; Grundman, Michael; Woodbury, Peter; Growdon, John; Cotman, Carl W.; Pfeiffer, Eric; Schneider, Lon S.; Thal, Leon J. (1997). A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease. New England Journal of Medicine, 336(17): 1216–1222. doi:10.1056/NEJM199704243361704.
236. SantaCruz, K. (2005). Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function. Science, 309(5733): 476–481. doi:10.1126/science.1113694.
237. Scheff, S. W.; Price, D. A.; Schmitt, F. A.; DeKosky, S. T.; Mufson, E. J. (2007). Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology, 68(18): 1501–1508. doi:10.1212/01.wnl.0000260698.46517.8f.
238. Schmand, B.; Huizenga, H. M.; van Gool, W. A. (2010). Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease. Psychological Medicine, 40(1): 135–. doi:10.1017/S0033291709991516
239. Schneider, L. S.; Farlow, M. R.; Henderson, V. W.; Pogoda, J. M. (1996). Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology, 46(6): 1580–1584. doi:10.1212/WNL.46.6.1580.
240. Selkoe, D. J. (2002). Alzheimer's Disease Is a Synaptic Failure., 298(5594): 789–791. doi:10.1126/science.1074069.
241. Selkoe, Dennis J. (2001). Alzheimer's Disease: Genes, Proteins, and Therapy. Physiological Reviews, 81(2): 741–766. doi:10.1152/physrev.2001.81.2.741.
242. Seppala TT,KoivistoAM,Hartikainen P, Helisalmi S, Soininen H, Herukka SK (2011) Longitudinal changes of CSF biomarkers in Alzheimer’s disease. J Alzheimers Dis 25,583-594 doi:10.3233/jad-2011-101911.

243. Serrano-Pozo, A.; Frosch, M. P.; Masliah, E.; Hyman, B. T. (2011). Neuropathological Alterations in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 1(1): a006189–a006189. doi:10.1101/cshperspect.a006189.
244. Shankar, G. M.; Bloodgood, B. L.; Townsend, M.; Walsh, D. M.; Selkoe, D. J.; Sabatini, B. L. (2007). Natural Oligomers of the Alzheimer Amyloid- Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway. Journal of Neuroscience, 27(11): 2866–2875. doi:10.1523/JNEUROSCI.4970-06.2007.
245. Shapiro, Samuel; Kelly, Judith P.; Rosenberg, Lynn; Kaufman, David W.; Helmrich, Susan P.; Rosenshein, Neil B.; Lewis, John L.; Knapp, Robert C.; Stolley, Paul D.; Schottenfeld, David (1985). Risk of Localized and Widespread Endometrial Cancer in Relation to Recent and Discontinued Use of Conjugated Estrogens. New England Journal of Medicine, 313(16): 969–972. doi:10.1056/nejm198510173131601.
246. Sherrington, R.; Rogaev, E. I.; Liang, Y.; Rogaeva, E. A.; Levesque, G.; Ikeda, M.; Chi, H.; Lin, C.; Li, G.; Holman, K. (1995). Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease., 375(6534): 754–760. doi:10.1038/375754a0.
247. Shi, Yang; Manis, Melissa; Long, Justin; Wang, Kairuo; Sullivan, Patrick M.; Remolina Serrano, Javier; Hoyle, Rosa; Holtzman, David M. (2019). Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. The Journal of Experimental Medicine, : jem.20190980–. doi:10.1084/jem.20190980
248. Shi, Yang; Yamada, Kaoru; Liddelow, Shane Antony; Smith, Scott T.; Zhao, Lingzhi; Luo, Wenjie; Tsai, Richard M.; Spina, Salvatore; Grinberg, Lea T.; Rojas, Julio C.; Gallardo, Gilbert; Wang, Kairuo; Roh, Joseph; Robinson, Grace; Finn, Mary Beth; Jiang, Hong; Sullivan, Patrick M.; Baufeld, Caroline; Wood, Michael W.; Sutphen, Courtney; McCue, Lena; Xiong, Chengjie; Del-Aguila, Jorge L.; Morris, John C.; Cruchaga, Carlos; Fagan, Anne M.; Miller, Bruce L.; Boxer, Adam L.; Seeley, William W.; Butovsky, Oleg; Barres, Ben A.; Paul, Steven M.; Holtzman, David M. (2017). ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature, doi:10.1038/nature24016.
249. Shinji Sudoh; Yuuki Kawamura; Shinji Sato; Rong Wang; Takaomi C. Saido; Fumitaka Oyama; Yoshiyuki Sakaki; Hiroto Komano; Katsuhiko Yanagisawa (1998). Presenilin 1 Mutations Linked to Familial Alzheimer's Disease Increase the Intracellular Levels of Amyloid β-Protein 1–42 and Its N-Terminally Truncated

Variant(s) Which Are Generated at Distinct Sites., 71(4): 1535–1543. doi:10.1046/j.1471-4159.1998.71041535.x.

250. Siderowf, A.; Xie, S. X.; Hurtig, H.; Weintraub, D.; Duda, J.; Chen-Plotkin, A.; Shaw, L. M.; Van Deerlin, V.; Trojanowski, J. Q.; Clark, C. (2010). CSF amyloid 1-42 predicts cognitive decline in Parkinson disease. Neurology, 75(12): 1055–1061. doi:10.1212/WNL.0b013e3181f39a78
251. Small, Scott A.; Petsko, Gregory A. (2020). Endosomal recycling reconciles the Alzheimerâ ™s disease paradox. Science Translational Medicine, 12(572): eabb1717–. doi:10.1126/scitranslmed.abb1717
252. Small, Scott A.; Simoes-Spassov, Sabrina; Mayeux, Richard; Petsko, Gregory A. (2017). Endosomal Traffic Jams Represent a Pathogenic Hub and Therapeutic Target in Alzheimer's Disease. Trends in Neurosciences, 40(10): 592–602. doi:10.1016/j.tins.2017.08.003.
253. Smith, M. A.; Harris, P. L. R.; Sayre, L. M.; Perry, G. (1997). Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proceedings of the National Academy of Sciences, 94(18): 9866–9868. doi:10.1073/pnas.94.18.9866.
254. Smith, Mark A.; Richey Harris, Peggy L.; Sayre, Lawrence M.; Beckman, Joseph S.; Perry, George (1997). Widespread Peroxynitrite-Mediated Damage in Alzheimer's Disease. The Journal of Neuroscience, 17(8): 2653–2657. doi:10.1523/JNEUROSCI.17-08-02653.1997.
255. Smith, Mark A.; Richey Harris, Peggy L.; Sayre, Lawrence M.; Beckman, Joseph S.; Perry, George (1997). Widespread Peroxynitrite-Mediated Damage in Alzheimer's Disease. The Journal of Neuroscience, 17(8): 2653–2657. doi:10.1523/JNEUROSCI.17-08-02653.1997.
256. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. JAMA 1997;277:813-7.
257. Snyder, Eric M; Nong, Yi; Almeida, Claudia G; Paul, Surojit; Moran, Timothy; Choi, Eun Young; Nairn, Angus C; Salter, Michael W; Lombroso, Paul J; Gouras, Gunnar K (2005). Regulation of NMDA receptor trafficking by amyloid-β., 8(8): 1051–1058. doi:10.1038/nn1503.
258. Spires-Jones, Tara L.; Hyman, Bradley T. (2014). The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer's Disease. Neuron, 82(4): 756–771. doi:10.1016/j.neuron.2014.05.004.

259. Stanley, Karen; Walker, Zuzana (2014). Do patients with young onset Alzheimer's disease deteriorate faster than those with late onset Alzheimer's disease? A review of the literature. International Psychogeriatrics, 26(12): 1945–1953. doi:10.1017/S1041610214001173
260. Steven T. DeKosky; Stephen W. Scheff (1990). Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity., 27(5): 457–464. doi:10.1002/ana.410270502.
261. Stewart, W. F.; Kawas, C.; Corrada, M.; Metter, E. J. (1997). Risk of Alzheimer's disease and duration of NSAID use. Neurology, 48(3): 626–632. doi:10.1212/wnl.48.3.626.
262. Stomrud, Erik; Hansson, Oskar; Blennow, Kaj; Minthon, Lennart; Londos, Elisabet (2007). Cerebrospinal Fluid Biomarkers Predict Decline in Subjective Cognitive Function over 3 Years in Healthy Elderly. Dementia and Geriatric Cognitive Disorders, 24(2): 118–124. doi:10.1159/000105017.
263. Strittmatter, W. J.; Weisgraber, K. H.; Huang, D. Y.; Dong, L. M.; Salvesen, G. S.; Pericak-Vance, M.; Schmechel, D.; Saunders, A. M.; Goldgaber, D.; Roses, A. D. (1993). Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.. Proceedings of the National Academy of Sciences, 90(17): 8098–8102. doi:10.1073/pnas.90.17.8098.
264. Sunderland, Trey; Linker, Gary; Mirza, Nadeem; Putnam, Karen T.; Friedman, David L.; Kimmel, Lida H.; Bergeson, Judy; Manetti, Guy J.; Zimmermann, Matthew; Tang, Brian; Bartko, John J.; Cohen, Robert M. (2003). Decreased β-Amyloid ₁₋₄₂ and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease. JAMA, 289(16): –. doi:10.1001/jama.289.16.2094.
265. Susanne Hauptmann; Uta Keil; Isabel Scherping; Astrid Bonert; Anne Eckert; Walter E. Müller (2006). Mitochondrial dysfunction in sporadic and genetic Alzheimer's disease., 41(7): 668–673. doi:10.1016/j.exger.2006.03.012.
266. SwerdlowRH, Burns JM, KhanSM(2010) The Alzheimer’s disease mitochondrial cascade hypothesis. J Alzheimers Dis 20(Suppl 2): S265-S279 doi:10.3233/JAD-2010-100339
267. Szekely, C. A.; Breitner, J.C.S.; Fitzpatrick, A. L.; Rea, T. D.; Psaty, B. M.; Kuller, L. H.; Zandi, P. P. (2008). NSAID use and dementia risk in the Cardiovascular Health Study*: Role of APOE and NSAID type. Neurology, 70(1): 17–24. doi:10.1212/01.wnl.0000284596.95156.48.

268. T. Ferretti, M.; C. Cuello, A. (2011). Does a Pro-Inflammatory Process Precede Alzheimers Disease and Mild Cognitive Impairment?. Current Alzheimer Research, 8(2): 164–174. doi:10.2174/156720511795255982.
269. Takashima, Akihiko; Wolozin, Benjamin; Buee, Luc (2019). [Advances in Experimental Medicine and Biology] Tau Biology Volume 1184 || ., 10.1007/978-981-32-9358-8 doi:10.1007/978-981-32-9358-8
270. Tan L, Yu JT, Tan MS, Liu QY, Wang HF, Zhang W, JiangT (2014) Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease.J Alzheimers Dis 40, 1017-1027doi:10.3233/jad-132144.
271. Tan, Lin; Yu, Jin-Tai; Hu, Nan; Tan, Lan (2013). Non-coding RNAs in Alzheimer's Disease. Molecular Neurobiology, 47(1): 382–393. doi:10.1007/s12035-012-8359-5
272. Tan, Lin; Yu, Jin-Tai; Liu, Qiu-Yan; Tan, Meng-Shan; Zhang, Wei; Hu, Nan; Wang, Ying-Li; Sun, Lei; Jiang, Teng; Tan, Lan (2014). Circulating miR-125b as a biomarker of Alzheimer's disease. Journal of the Neurological Sciences, 336(1-2): 52–56. doi:10.1016/j.jns.2013.10.002.
273. Teresa Gomez-Isla; Howard L. West; G. William Rebeck; Steven D. Harr; John H. Growdon; Joseph J. Locascio; Thomas T. Perls; Lewis A. Lipsitz; Dr. Bradley T. Hyman (1996). Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease., 39(1): 62–70. doi:10.1002/ana.410390110.
274. Teresa Gómez-Isla; Richard Hollister; Howard West; Stina Mui; John H. Growdon; Ronald C. Petersen; Joseph E. Parisi; Dr Bradley T. Hyman (1997). Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease., 41(1): 17–24. doi:10.1002/ana.410410106.
275. Terry, R D; Davies, P (1980). Dementia of the Alzheimer Type. Annual Review of Neuroscience, 3(1): 77–95. doi:10.1146/annurev.ne.03.030180.000453.
276. The Canadian Study of Health and Aging. The Canadian Study of Health and Aging: risk factors for Alzheimer's disease. Neurology 1994;44:2073-80.doi: 10.1212/wnl.44.11.2073.
277. Thinakaran, G.; Koo, E. H. (2008). Amyloid Precursor Protein Trafficking, Processing, and Function. Journal of Biological Chemistry, 283(44): 29615–29619. doi:10.1074/jbc.r800019200.
278. Thomas J. Montine; Creighton H. Phelps; Thomas G. Beach; Eileen H. Bigio; Nigel J. Cairns; Dennis W. Dickson; Charles Duyckaerts; Matthew P. Frosch; Eliezer Masliah; Suzanne S. Mirra; Peter T. Nelson; Julie A. Schneider; Dietmar Rudolf Thal; John Q.

Trojanowski; Harry V. Vinters; Bradley T. Hyman (2012). National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach., 123(1): 1–11. doi:10.1007/s00401-011-0910-3.

279. Tom, Sarah E.; Phadke, Manali; Hubbard, Rebecca A.; Crane, Paul K.; Stern, Yaakov; Larson, Eric B. (2020). Association of Demographic and Early-Life Socioeconomic Factors by Birth Cohort With Dementia Incidence Among US Adults Born Between 1893 and 1949. JAMA Network Open, 3(7): e2011094–. doi:10.1001/jamanetworkopen.2020.11094.
280. Tony Wyss-Coray; Lennart Mucke (2002). Inflammation in Neurodegenerative Disease—A Double-Edged Sword., 35(3): 0–432. doi:10.1016/s0896-6273(02)00794-8.
281. Tuszynski, Mark H.; Yang, Jennifer H.; Barba, David; U, Hoi-Sang; Bakay, Roy A. E.; Pay, Mary M.; Masliah, Eliezer; Conner, James M.; Kobalka, Peter; Roy, Subhojit; Nagahara, Alan H. (2015). Nerve Growth Factor Gene Therapy. JAMA Neurology, doi:10.1001/jamaneurol.2015.1807.
282. U. BEFFERT; J. POIRIER (1996). Apolipoprotein E, Plaques, Tangles and Cholinergic Dysfunction in Alzheimer's Disease., 777(none): 166–174. doi:10.1111/j.1749-6632.1996.tb34415.x.
283. Uchikado, Hirotake; DelleDonne, Anthony; Ahmed, Zeshan; Dickson, Dennis W. (2006). Lewy Bodies in Progressive Supranuclear Palsy Represent an Independent Disease Process. Journal of Neuropathology and Experimental Neurology, 65(4): 387–395. doi:10.1097/01.jnen.0000218449.17073.43.
284. Valérie Leduc; Stéphanie Jasmin-Bélanger; Judes Poirier (2010). APOE and cholesterol homeostasis in Alzheimer's disease., 16(10): 0–477. doi:10.1016/j.molmed.2010.07.008.
285. van der Kant, Rik; Goldstein, Lawrence S. B.; Ossenkoppele, Rik (2019). Amyloid-β-independent regulators of tau pathology in Alzheimer disease. Nature Reviews Neuroscience, doi:10.1038/s41583-019-0240-3.
286. van Leeuwen, F. W. (1998). Frameshift Mutants of Amyloid Precursor Protein and Ubiquitin-B in Alzheimer's and Down Patients. Science, 279(5348): 242–247. doi:10.1126/science.279.5348.242.
287. van Vliet, D.; de Vugt, M. E.; Bakker, C.; Pijnenburg, Y. A. L.; Vernooij-Dassen, M. J. F. J.; Koopmans, R. T. C. M.; Verhey, F. R. J. (2013). Time to diagnosis in young-onset dementia as compared with late-onset dementia. Psychological Medicine, 43(2): 423–432. doi:10.1017/s0033291712001122.

288. Veronese, N.; Zurlo, A.; Solmi, M.; Luchini, C.; Trevisan, C.; Bano, G.; Manzato, E.; Sergi, G.; Rylander, R. (2015). Magnesium Status in Alzheimer's Disease: A Systematic Review. American Journal of Alzheimer's Disease and Other Dementias, : 1533317515602674–. doi:10.1177/1533317515602674.
289. Vlad, S. C.; Miller, D. R.; Kowall, N. W.; Felson, D. T. (2008). Protective effects of NSAIDs on the development of Alzheimer disease., 70(19): 1672–1677. doi:10.1212/01.wnl.0000311269.57716.63
290. Wahba, Sanaa M.R.; Darwish, Atef S.; Kamal, Sara M. (2016). Ceria-containing uncoated and coated hydroxyapatite-based galantamine nanocomposites for formidable treatment of Alzheimer's disease in ovariectomized albino-rat model. Materials Science and Engineering: C, : S0928493116303393–. doi:10.1016/j.msec.2016.04.041
291. Wallace, D. C. (1999). Mitochondrial Diseases in Man and Mouse. Science, 283(5407): 1482–1488. doi:10.1126/science.283.5407.1482.
292. Wallin, Å.K.; Blennow, K.; Andreasen, N.; Minthon, L. (2006). CSF Biomarkers for Alzheimer’s Disease: Levels of β-Amyloid, Tau, Phosphorylated Tau Relate to Clinical Symptoms and Survival. Dementia and Geriatric Cognitive Disorders, 21(3): 131–138. doi:10.1159/000090631.
293. Walsh, D. M. (2005). Certain Inhibitors of Synthetic Amyloid -Peptide (A) Fibrillogenesis Block Oligomerization of Natural A and Thereby Rescue Long-Term Potentiation. Journal of Neuroscience, 25(10): 2455–2462. doi:10.1523/JNEUROSCI.4391-04.2005
294. Wang, C., Yu, J.-T., Wang, H.-F., Jiang, T., Tan, C.-C., Meng, X.-F., … Tan, L. (2014). Meta-Analysis of Peripheral Blood Apolipoprotein E Levels in Alzheimer’s Disease. PLoS ONE, 9(2): e89041. doi:10.1371/journal.pone.0089041
295. Wang, H.-Y. (2000). beta -Amyloid1-42 Binds to alpha 7 Nicotinic Acetylcholine Receptor with High Affinity. IMPLICATIONS FOR ALZHEIMER'S DISEASE PATHOLOGY. Journal of Biological Chemistry, 275(8): 5626–5632. doi:10.1074/jbc.275.8.5626.
296. Wang, Liang; Brier, Matthew R.; Snyder, Abraham Z.; Thomas, Jewell B.; Fagan, Anne M.; Xiong, Chengjie; Benzinger, Tammie L.; Holtzman, David M.; Morris, John C.; Ances, Beau M. (2013). Cerebrospinal Fluid Aβ42, Phosphorylated Tau ₁₈₁, and Resting-State Functional Connectivity. JAMA Neurology, doi:10.1001/jamaneurol.2013.3253

297. Wang, Zengjin; Wei, Xiaomin; Yang, Junlin; Suo, Jinning; Chen, Jingyi; Liu, Xianchen; Zhao, Xiulan (2016). Chronic exposure to aluminum and risk of Alzheimer's disease: A meta-analysis. Neuroscience Letters, 610: 200–206. doi:10.1016/j.neulet.2015.11.014.
298. Wattmo, Carina; Wallin, Åsa K. (2017). Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years. Alzheimer's Research & Therapy, 9(1): 70–. doi:10.1186/s13195-017-0294-2.
299. Weekes, Brendan Stuart Hackett (2020). Aphasia in Alzheimerâ ™s Disease and Other Dementias (ADOD): Evidence From Chinese. American Journal of Alzheimer's Disease & Other Dementiasr, 35: 153331752094970–. doi:10.1177/1533317520949708.
300. Weggen, S. (2003). Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid 42 Production by Direct Modulation of -Secretase Activity., 278(34): 31831–31837. doi:10.1074/jbc.m303592200.
301. William L Klein; Grant A Krafft; Caleb E Finch (2001). Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?., 24(4): 0–224. doi:10.1016/s0166-2236(00)01749-5.
302. Williamson, Jeff D.; Pajewski, Nicholas M.; Auchus, Alexander P.; Bryan, R. Nick; Chelune, Gordon; Cheung, Alfred K.; Cleveland, Maryjo L.; Coker, Laura H.; Crowe, Michael G.; Cushman, William C.; Cutler, Jeffrey A.; Davatzikos, Christos; Desiderio, Lisa; Erus, Guray; Fine, Larry J.; Gaussoin, Sarah A.; Harris, Darrin; Hsieh, Meng-Kang; Johnson, Karen C.; Kimmel, Paul L.; Tamura, Manjula Kurella; Launer, Lenore J.; Lerner, Alan J.; Lewis, Cora E.; Martindale-Adams, Jennifer; Moy, Claudia S.; Nasrallah, Ilya M.; Nichols, Linda O.; Oparil, Suzanne; Ogrocki, Paula K.; Rahman, Mahboob; Rapp, Stephen R.; Reboussin, David M.; Rocco, Michael V.; Sachs, Bonnie C.; Sink, Kaycee M.; Still, Carolyn H.; Supiano, Mark A.; Snyder, Joni K.; Wadley, Virginia G.; Walker, Jennifer; Weiner, Daniel E.; Whelton, Paul K.; Wilson, Valerie M.; Woolard, Nancy; Wright, Jackson T.; Wright, Clinton B. (2019). Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia. JAMA, doi:10.1001/jama.2018.21442.
303. Wolfe, Michael S. (2012). Processive proteolysis by γ-secretase and the mechanism of Alzheimer's disease. Biological Chemistry, 393(9): –. doi:10.1515/hsz-2012-0140.
304. Wu, Jessica W; Hussaini, Syed A; Bastille, Isle M; Rodriguez, Gustavo A; Mrejeru, Ana; Rilett, Kelly; Sanders, David W; Cook, Casey; Fu, Hongjun; Boonen, Rick A C M; Herman, Mathieu; Nahmani, Eden; Emrani, Sheina; Figueroa, Y Helen; Diamond, Marc I; Clelland, Catherine L; Wray, Selina; Duff, Karen E (2016). Neuronal activity enhances tau propagation and tau pathology in vivo. Nature Neuroscience, doi:10.1038/nn.4328.

305. Wu, Yu-Tzu; Beiser, Alexa S.; Breteler, Monique M. B.; Fratiglioni, Laura; Helmer, Catherine; Hendrie, Hugh C.; Honda, Hiroyuki; Ikram, M. Arfan; Langa, Kenneth M.; Lobo, Antonio; Matthews, Fiona E.; Ohara, Tomoyuki; Pérès, Karine; Qiu, Chengxuan; Seshadri, Sudha; Sjölund, Britt-Marie; Skoog, Ingmar; Brayne, Carol (2017). The changing prevalence and incidence of dementia over time — current evidence. Nature Reviews Neurology, doi:10.1038/nrneurol.2017.63.
306. Xavier Mungarro-Menchaca; Patricia Ferrera; Julio Morán; Clorinda Arias (2002). β-Amyloid peptide induces ultrastructural changes in synaptosomes and potentiates mitochondrial dysfunction in the presence of ryanodine., 68(1): 89–96. doi:10.1002/jnr.10193.
307. Xu, He; Finkelstein, David I.; Adlard, Paul A. (2014). Interactions of metals and Apolipoprotein E in Alzheimerâ€™s disease. Frontiers in Aging Neuroscience, 6:. doi:10.3389/fnagi.2014.00121.
308. Yaakov Stern (2012). Cognitive reserve in ageing and Alzheimer's disease., 11(11): –. doi:10.1016/s1474-4422(12)70191-6.
309. Yamada, K.; Holth, J. K.; Liao, F.; Stewart, F. R.; Mahan, T. E.; Jiang, H.; Cirrito, J. R.; Patel, T. K.; Hochgrafe, K.; Mandelkow, E.-M.; Holtzman, D. M. (2014). Neuronal activity regulates extracellular tau in vivo. Journal of Experimental Medicine, 211(3): 387–393. doi:10.1084/jem.20131685.
310. Yan, Shi Du; Chen, Xi; Fu, Jin; Chen, Ming; Zhu, Huaijie; Roher, Alex; Slattery, Timothy; Zhao, Lei; Nagashima, Mariko; Morser, John (1996). RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease., 382(6593): 685–691. doi:10.1038/382685a0.
311. Yong Shen; Seppo Meri (2003). Yin and Yang: complement activation and regulation in Alzheimer’s disease., 70(6): 0–472. doi:10.1016/j.pneurobio.2003.08.001.
312. Yuan Yuan Hu; Shan Shu He; Xiaochuan Wang; Qiu Hong Duan; Inge Grundke-Iqbal; Khalid Iqbal; Jianzhi Wang (2002). Levels of Nonphosphorylated and Phosphorylated Tau in Cerebrospinal Fluid of Alzheimer's Disease Patients: An Ultrasensitive Bienzyme-Substrate-Recycle Enzyme-Linked Immunosorbent Assay., 160(4): 0–1278. doi:10.1016/s0002-9440(10)62554-0.
313. Zhu XC, Tan L, Wang HF, et al. Rate of early onset Alzheimer’s disease: a systematic review and meta-analysis. Ann Transl Med, 2015; 3(3): 38. doi:10.3978/j.issn.2305-5839.2015.01.19. [PMC free article] [PubMed] [CrossRef] [Google Scholar] doi:10.3978/j.issn.2305.